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The advances of immune checkpoint blockade therapies have reshaped the cancer 
treatment. However, a less than 20% response rate was reported in Triple-Negative Breast Cancer 
(TNBC) owing to the immunosuppressive tumor microenvironment (TME). Immunosuppressive 
TME is characterized with low T cell infiltration, presence of abundant immunosuppressive cells 
and low mutational burden. In this work, we employed three different, nano-based strategies to 
remodel the immunosuppressive TME, respectively.  
High tumor immunogenicity would be achieved by generation of immunogenic cell death 
(ICD) of tumor cells [1]. To increase immunogenicity within the TME, we developed a liposome 
formulation to deliver a potential immunogenic cell death (ICD) inducing agent, 17-(allylamino)-
17-demethoxygeldanamycin (17-AAG), in a tumor targeted manner to reverse the 
immunosuppressive microenvironment and facilitate the checkpoint blockade immunotherapy.  
Adipocytes are the primary cellular component within the TNBC TME. In this study, we 
first investigated the biological effect of tumor-associated adipocyte (TAA) within breast cancer 
TME and identified C-C Motif Chemokine Ligand 2 (CCL2) as the key mediator which mainly 
secreted by TAA into the extracellular environment. We designed a protein trap which binds with 
CCL2 with high affinity and formulated lipid-protamine-DNA nanoparticles to locally express and 
trap CCL2 and ameliorated the immunosuppressive TME. We further demonstrated that pCCL2 
trap could facilitate the pPD-L1 based checkpoint blockade immunotherapy.  
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Arsenic is an FDA approved chemotherapy with high mutagenicity and toxicity. Here we 
developed a tumor targeted delivery platform-lipidic calcium arsenic nanoparticles (LCA NPs) to 
specifically deliver arsenic into poorly immunogenic TNBC tumor to attempt generating a 
neoantigen repertoire for chemo-immunotherapy. LCA NPs achieved the tumor specific delivery 
and accumulation of arsenic, which is a key to induce mutation through DNA damage as shown 
by the comet assay. In addition, tumor-targeted delivery of arsenic successfully reprogrammed the 
immunosuppressive TME in an orthotopic murine TNBC model.  
In conclusion, our work provided a feasible, effective and safe way for TME modulation 
in TNBC, and opens up possibilities for the development of chemo-immunotherapy for 
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CHAPTER 1: MODULATION OF TUMOR MICROENVIRONMENT FOR 
IMMUNOTHERAPY: FOCUS ON NANOMATERIAL-BASED STRATEGIES1 
 
1. Summary 
Recent advances in the field of immunotherapy have profoundly opened up the potential 
for improved cancer therapy and reduced side effects. However, the tumor microenvironment 
(TME) is highly immunosuppressive, therefore, clinical outcomes of currently available cancer 
immunotherapy are still poor. Recently, nanomaterial-based strategies have been developed to 
modulate the TME for robust immunotherapeutic responses. In this review, the immunoregulatory 
cell types (cells relating to the regulation of immune responses) inside the TME in terms of 
stimulatory and suppressive roles are described, and the technologies used to identify and quantify 
these cells are provided. In addition, recent examples of nanomaterial-based cancer 
immunotherapy are discussed, with particular emphasis on those designed to overcome barriers 
caused by the complexity and diversity of TME.  
2. Introduction 
Recent knowledge of the crosstalk between cancer cells and the host immune system 
(termed the cancer-immunity cycle) has opened up the potential for cancer immunotherapy [2]. 
The clinical promise of different strategies such as monoclonal antibodies (mAbs, conjugated with 
and without drugs) [3], cancer vaccines [4], adoptive T cell therapy [5] and immune checkpoint 
inhibitors (mostly antibodies) [6], has underscored the status of immunotherapy as a pillar of 
 
1 This Chapter previously appeared as a review article in Theranostics. The original citation is as follows: Liu, Y., J. 
Guo, and L. Huang, Modulation of tumor microenvironment for immunotherapy: focus on nanomaterial-based 
strategies. Theranostics, 2020. 10(7): p. 3099-3117. 
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cancer treatment. However, the neoplastic foci (unlike hematologic malignancies) is normally 
surrounded by immune cells, fibroblasts, soluble signaling molecules, blood vessels, and the 
extracellular matrix (ECM) (see more details in [7]). These cells/components in the tumor 
microenvironment (TME) cause serious resistance to currently available immune-based therapies 
[7]. For example, the adoptive transfer of genetically engineered T cells expressed with chimeric 
antigen receptors (CARs) has achieved promising results in the treatment of acute lymphocytic 
leukemia (one of blood cancers) with up to 90% of five-year overall survival, but this treatment 
has been significantly limited in solid tumors [8]. Therapeutic efficacy of antibody-drug conjugates 
and cancer vaccines is also largely attenuated by immunosuppression caused by the TME [9]. In 
addition, the blockade of immune checkpoint molecules (e.g. programmed cell death protein 1, 
PD-1; cytotoxic T lymphocyte-associated protein 4, CTLA-4) using antibodies has demonstrated 
great promise for sculpting tumor immunogenicity in certain solid tumors (e.g. melanoma and non-
small cell lung cancer) [9]; however, response rates to immune checkpoint inhibitors tremendously 
vary in different tumor types, which is mainly attributed to the complex nature of TME [10]. 
Recently, increasing research in nanomaterials has offered great potential for the 
improvement of cancer immunotherapy [11], but the immunosuppressive TME still limits the 
efficacy. Therefore, it is really of critical importance to understand the complexity and diversity 
of TME. Recent advances in technologies such as high-solution imaging, flow cytometry and next-
generation sequencing are anticipated to provide a comprehensive view of TME constituents [7], 
which will inspire the development of novel nanoformulations to advance cancer immunotherapy. 
In this review, the immunoregulatory cells (cells relating to the regulation of immune responses) 
in terms of stimulatory and suppressive roles in the TME are described, and the techniques used 
to characterize and quantify them are provided. This review will also discuss different nanoparticle 
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(NP) strategies under investigation for cancer immunotherapy, with specific emphasis on those 
designed for circumventing barrages caused by the TME. 
3. Immunoregulatory Cell Types in TME 
Tumorigenesis as a complex and dynamic process is generally comprised of three phases 
namely initiation, development and metastasis. The interactions between malignant/non-malignant 
cells and cellular/non-cellular components form a microenvironment surrounding the neoplastic 
foci [7]. Inside there, the ECM (a complex network of proteins, proteoglycans and enzymes) 
provides the physical and biochemical support for surrounding cells, and the crosstalk between 
tumor cells, immune cells and stromal cells via the secretion of cytokines and chemokines causes 
the escape of immunosurveillance for tumor progression [12]. The details of tumor/non-tumor cell 
communications and cell-ECM interactions have been substantially studied [13], which assist in 
understanding the structural and physiological obstacles associated with the TME and 
consequently improving cancer therapies. Generally, cells inside the TME [14] include: immune 
cells (e.g. dendritic cells, lymphocytes, macrophages and myeloid-derived suppressor cells 
(MDSCs)), cells of mesenchymal origin (e.g. fibroblasts, myofibroblasts, mesenchymal stromal 
cells), and vascular cells (e.g. endothelial cells and pericytes). 
In this section, we will discuss the cell types within the TME in terms of 
immunostimulatory and immunosuppressive roles (Table 1) and describe technologies for 
characterization and quantification of these cells, hoping to understand the mechanisms of 
immunotherapy resistance, identify potential therapeutic targets, and advance antitumor immunity 






Table 1. The commonly used phenotypic markers for immune cells within the TME in 
terms of stimulatory/suppressive roles. 
3.1 Immunostimulatory cells 
Dendritic cells (DCs): It is known that a large number of genetic mutations and the failure 
of normal cellular regulatory processes are evident in cancers. These abnormalities cause the 
presence of neoantigens, differentiation antigens, or cancer/testis antigens (together termed tumor-
associated antigens (TAAs)), which result in the presentation of peptides bound to the major 
histocompatibility class I (MHC-I), distinguishing cancer cells from the normal cell types [29]. At 
the beginning of cancer-immunity cycle depicted by Chen and Mellman (step 1 of Figure 1.1) [2], 
TAAs are released from dying tumor cells and captured by antigen-presenting cells (APCs). The 
Cell Subtypes Markers Ref. 
Immunostimulatory   
DCs CD11b+ MHCII+ [15] 
Cytotoxic T cells CD3+ CD8+ [16] 
Helper T cells CD3+ CD4+ [17] 
Memory T cells CD44+ CD62L+ CD3+ [18] 
Follicular B cells IgD+CD21+CD22+ CD23+ [19] 
Plasma cells CD138+CD38+ [20] 
Memory B cells CD20+CD27+CD40+CD80+ [21] 




M1 cells F4/80+ CD86+ CD80+ [24] 
Immunosuppressive   
MDSCs CD11b+ Gr-1+ [25] 
M2 cells F4/80+ CD206+ CD163+ [24] 




Bregs CD19+ IL-10+ [28] 
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professional APCs mainly include DCs, macrophages and B cells, and among these, DCs play 
critical roles in starting and regulating the anticancer immunity [30]. Subsequently, TAAs are 
bound to MHC-I/MHC-II of mature DCs (step 2 of Figure 1.1). When mature DCs migrate into 
tumor-draining lymph nodes, they present TAAs to T cells, which lead to the priming and 
activation of effector T cells against TAAs (step 3 of Figure 1.1). The function of DCs can be 
regulated by a complex network involving cytokines, chemokines and damage-associated 
molecular patterns (DAMPs) (Figure 1.1; also see review in [30]).  
 
Figure 1.1 The cancer-immunity cycle in tandem with a summary of stimulatory and inhibitory components. 
As depicted by Chen and Mellman, this cycle is comprised of 1) release of tumor cell antigens by dying cancer cells, 
2) antigen presentation by DCs, 3) priming and activation of T cells, 4) trafficking and 5) infiltration of activated T 
cells to tumors, 6) recognition of tumor cells by activated T cells, and 7) killing of tumor cells. The stimulatory and 
inhibitory factors together form an immune regulatory network for the modulation of cancer-immunity cycle. This 
figure has been modified from [2] and [11]. 
 
The phenotypic maturation of DCs is associated with the upregulation of surface markers 
such as CD80, CD83 and CD86 along with the MHC molecules, whereas the expression of these 
markers is negative or low in immature or semi-mature DCs [31]. When DCs become mature, they 
secrete medium/high levels of pro-inflammatory or immunostimulatory cytokines (e.g. IL-12, IL-
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23 and IL-1β) and low level of immunosuppressive cytokines (e.g. IL-10 and TGF-β) [31]. In 
contrast to mature DCs, immature or semi-mature counterparts are devoid of the capacity to prime 
and activate T cells against tumors, or may even cause T cell anergy and induce tolerance therefore 
compromising antitumor immunity [30]. Recently, the stimulatory and inhibitory factors 
associated with DC maturation have been used as therapeutic means or targets for developing 
novel nanomaterial-based strategies.  
Cytotoxic T lymphocytes (CTLs): As shown in step 3 of Figure 1.1, naive CD8 T cells 
become CTLs when TAAs bound on MHC-I of DCs are interacted with the T-cell receptor (TCR, 
a disulfide-linked membrane-anchored heterodimeric protein complex composed of CD3 and 
highly variable alpha and beta chains [32]). CTLs are capable of trafficking through tissues (e.g. 
blood and lymphatic vessels) (step 4 of Figure 1.1) and infiltrating into tumors (step 5 of Figure 
1.1). It is known that the trafficking and infiltration of CTLs are tightly upregulated by a complex 
interactions between T cells and endothelial cells, mainly including [32] 1) the expression of 
homing molecules (e.g. PSGL-1 and CD44) on CTLs that can facilitate them to migrate into 
tumors; 2) a temporary attachment of CTLs onto the endothelium by binding P- and E-selectins 
via homing molecules; 3) the expression of chemokine receptors (e.g. CXCR3) on CTLs that can 
bind chemokines (e.g. CXCL9 and CXCL10) released from the TME; 4) the activation of integrins 
(e.g. LFA-1 and VLA-4) on CTLs that can bind integrin ligands (e.g. ICAM-1 and VCAM-1), 
which form a firm adhesion between CTLs and the endothelium, leading to extravasation of CTLs 
into the tumor bed. Subsequently, CTLs release the cytotoxic mediators such as IFN-γ, granzymes 
or perforin to kill cancer cells in a TCR-dependent manner (steps 6 and 7 of Figure 1.1). 
However, when CTLs enter the TME, they encounter an immunosuppressive milieu, in 
which inhibitory components derived from tumor cells and stromal cells can affect the phenotype 
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and function of CTLs and finally turn them into “exhausted” state (e.g. decreased proliferation and 
reduced production of cytotoxic mediators). For example, the activity of CTLs is significantly 
dampened by immunosuppressive mediators produced by tumor cells such as indoleamine 2,3-
dioxygenase 1 (IDO-1), programmed death-ligand 1 (PD-L1), cyclooxygenase type 2 (COX‐2), 
and signal transducer and activator of transcription 3 (STAT3) [33]. In addition, a number of 
cytokines released from tumor-associated fibroblasts (TAFs), myeloid-derived suppressor cells 
(MDSCs), macrophage type 2 (M2) cells and regulatory T cells (Tregs) can negatively regulate 
CTL-mediated cancer killing (step 7 of Figure 1.1; see below discussion). Therefore, the 
nanomaterial-based strategies targeting these aforemetioned inhibitory mediators may potentially 
relieve the exhaustion of CTLs and rescue their cytotoxic function for antitumor immunity. 
T helper (Th) cells: The cell-mediated antitumor immunity (an immune response that is not 
involved with antibodies) has been largely attributed to CD8+ CTLs, however, emerging evidence 
indicates that CD4+ Th cells also play significant roles in the initiation and maintenance of 
antitumor effects. When antigens bound onto MHC-II of APCs interact with the TCR, naive CD4+ 
T cells are generally differentiated into Th1, Th2, Th17 and Th9 subtypes [34].  
The differentiation of Th1 requires IL-2, IL-12 and IFN-γ, and Th1 cells release IFN-γ, IL-
2 and TNF-α for the assistance of CTL differentiation, activation of macrophage type 1 (M1) cells, 
and mediation of cell-mediated immunity [35]. The differentiation of Th2 requires IL-4, IL-6 and 
IL-10, and Th2 cells secrete IL-4, IL-5 and IL-13 for coordinating humoral immunity (an immune 
response that is involved with antibodies) (see below discussion). Although Th1 and Th2 subsets 
are both known to induce antitumor immunity, IFN-γ-secreting Th1 cells have demonstrated better 
efficacy in this role [34]. However, the level of Th2 cytokines within the TME is significantly 
higher than that of Th1 cytokines, which prevent the production of Th1 cells and activation of 
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CTLs [35]. In addition, Th17 cells as an independent CD4+ lineage from either Th1 or Th2 have 
demonstrated a paradox of its function in tumor immunity [36]. Although Th17 mediates antitumor 
immune responses by means of stimulating effector CTLs, they may increase tumor progression 
through promoting angiogenesis and immunosuppressive events [36]. Recently, it has been 
reported that a subset of CD4+ Th cells namely Th9 possess less-exhausted cytolytic function as 
strong as Th1 cells and demonstrate hyperproliferative feature to persist as long as Th17 cells [37]. 
Th9-mediated anticancer efficacy is highly relied on IL-9 and upregulated expression of Eomes 
(Eomesodermin; the effector master regulator that controls granzyme expression) and Traf6 (tumor 
necrosis factor receptor (TNFR)-associated factor 6; one of NF-κB upstream signaling proteins). 
As a result, tumor-specific Th9 cells eliminated the advanced late-stage melanoma and protected 
surviving animals against the tumor rechallenge [37], indicating the significant role of Th9 cells 
in adoptive cancer therapy. As Th subsets are generally supposed as a double-edged sword in 
tumor immunology, nanomaterial-based therapeutic approaches that balance these Th cells hold 
the promise for cancer immunotherapy. 
B cells: The critical contributions of T cells in antitumor immunity have been substantially 
investigated and well established. In contrast, the immunologic roles of B cells in response to 
tumors are less well studied. B cells are comprised of functionally distinct subpopulations, and the 
balance among these has a significant impact on tumoricidal activity [38]. When B cells are 
activated under the stimulation of B cell receptor (BCR) pathway, microRNA pathway, and Toll-
like receptor (TLR) pathway [39], they exert antitumor immunity by means of producing 
antibodies, cytokines and chemokines [40], acting as local APCs [41], and forming tertiary 
lymphoid structures (TLS, ectopic lymphoid-like structures for long-term antitumor immunity) 
[42]. A subpopulation of B cells termed plasma cells can produce antibodies for antitumor 
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responses, which mainly include antibody-dependent cell-mediated cytotoxicity (ADCC) and 
complement-dependent cytotoxicity (CDC). In addition, mature follicular B cells (FOB, a subset 
of B cells) can differentiate into Be-1 and Be-2 cells, which produce cytokines such as IFN-γ, 
TNF-α, IL-2 and IL-12 for enhancing the antitumor immunity of T and NK cells [40]. When 
stimulated by the CD40-CD40 ligand (CD40L) signaling pathway, B cells become local APCs in 
tumors, which maintain the survival and proliferation of tumor infiltrating T cells for durable 
antitumor responses [41]. However, B cells are significantly shaped inside the TME, which impair 
the activity of immunostimulatory B cells but result in differentiation of B cells into an 
immunosuppressive subtype termed regulatory B cells (Bregs, see below review).  
Natural Killer (NK) cells: They have long been known as a subclass of cytotoxic 
lymphocytes that are critical for innate immunity against virus-infected and malignant cells [43]. 
Recently, emerging evidence has displayed that abnormal cells can be distinguished from healthy 
cells through a group of functional receptors (e.g. inhibitory and activating receptors) on the 
surface of NK cells [43]. The acquisition of corresponding ligands in combination with reduced 
expression of MHC-I molecules on aberrant cells will exert the cytotoxicity of NK cells against 
assaults (e.g. viruses and cancers) while ensuring self-tolerance [44]. The cytotoxic activity of NK 
cells is relied on cytokines such as IL-2, IL-12, IL-15 and IFN-α/β [44]. The NK cells release IFN-
γ to promote the expression levels of MHC-I on cancer cells and MHC-II on APCs, facilitating the 
connection of innate and adaptive immunities [45]. The NK cells are also able to govern the growth 
and differentiation of DCs and T cells; for example, IFN-γ secreted by NK cells can activate DCs 
for priming subsequent T-cell responses [44, 45]. However, the development of therapeutic means 
based on NK cells remains a challenge, as the inhibitory factors produced by the TME can 
significantly cause the dysfunction of NK cells [46]. Recent strategies (e.g. checkpoint inhibitors 
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and therapeutic antibodies) have demonstrated the potential to reverse NK cell dysfunction 
therefore boosting antitumor immunity [47].  
Macrophage type 1 (M1) cells: Tumor-associated macrophages (TAMs) are a population 
of immune cells within the TME of solid tumors [48]. TAMs are recruited into tumors by 
chemokines (e.g. CCL2), cytokines (e.g. VEGF, PDGF and M-CSF), and other factors (e.g. 
fibronectin, fibrinogen, cleavage products of ECM proteins). As two key subtypes of TAMs, the 
classically and alternatively activated macrophages (termed M1 and M2 respectively) play distinct 
roles in the processes of immunosurveillance and angiogenesis underlying tumor formation, 
development, and metastasis [48]. When TAMs are under the stimulation of bacterial products 
(e.g. lipopolysaccharide, LPS) and Th1 cytokines (e.g. IFN-γ and TNF-α), they are driven towards 
M1. The M1 subtype is normally characterized by immunostimulatory activity and antitumor 
function [49]. For example, M1 cells release Th1 cytokines (e.g. IFN-γ, IL-2 and TNF-α) and 
chemokines (e.g. CXCL9 and CXCL10) for directly killing tumor cells as well as for indirectly 
augmenting the cytotoxic activity of T cells [49]. In addition, M1 cells are capable of normalizing 
the tortuous vasculature [50], which can remodel the TME and overcome resistance to cancer 
therapy. In contrast, M2 cells have a significant impact on tumor progression by promoting genetic 
instability, supporting tumor growth and metastasis, and orchestrating tumor immunity (see below 
discussion). 
3.2 Immunosuppresive cells 
Myeloid-derived suppressor cells (MDSCs): It is known that mononuclear cells 
(monocytes, they are terminally differentiated into macrophages and DCs) and granulocytes (for 
example, neutrophils as the most abundant representative) originate from hematopoietic stem cells 
via common myeloid progenitors within the bone marrow (BM) [51]. The activity of these myeloid 
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cells is tightly governed by a network of signals from pathogens in the form of TLR ligands, 
DAMPs and/or pathogen-associated molecular patterns (PAMPs) [51]. These signals are often 
strong but end in a short duration. The response to the signals leads to a rapid mobilization of 
monocytes and neutrophils from the BM, the significantly enhanced phagocytosis, a generation of 
pro-inflammatory cytokines, and the upregulation of MHC class II and costimulatory molecules 
[52]. In contrast, the signals generated by chronic conditions (e.g. cancers) are relatively weak but 
sustain for a long while [53]. When the nature of myeloid cells is deformed under cancerous 
condition, monocytes/neutrophils demonstrate immature phenotype and morphology, ineffective 
phagocytic activity, and high expression of anti-inflammatory cytokines [54]. Consequently, these 
immature myeloid cells are proliferated and converted to MDSCs. MDSCs always coexist with 
normal monocytes and neutrophils in cancer patients, but the number of MDSCs is increased 
during tumor progression and becomes dominant, which suppress the adaptive immunity and 
facilitate tumor progression and metastasis [54]. 
MDSCs consist of two main subpopulations namely monocytic (M-) [55] and 
polymorphonuclear (PMN-) [56] MDSCs. Increasing evidence indicates that M-MDSCs are 
phenotypically and morphologically similar to monocytes, and PMN-MDSCs are similar to 
neutrophils [57]. M-MDSCs (CD11b+Gr1low phenotype) rapidly differentiate into TAMs within 
tumors, in which these terminally differentiated myeloid cells (most likely macrophage type 2, see 
below discussion) inhibit immune responses and promote tumor development [57]. On the other 
hand, PMN-MDSCs (often referred as immunosuppressive neutrophils, with a CD11b+Gr1high 
phenotype) are propagated inside tumors in which they become the dominant subpopulation of 
neutrophils [58]. As MDSCs and monocytes/neutrophils share a common number of markers and 
are identical in morphology, there is still a debate associated with the relationship between these 
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cells. Therefore, future studies are needed to solve the controversy and confusion surrounding the 
true nature of MDSCs (see review in [59]).  
The migration of MDSCs to tumors is achieved by chemokines, and among these, CCL2 
and CCL5 are considered the main chemokines underlying the MDSC migration [60, 61]. The 
other chemokines such as CCL15, CXCL5, CXCL6, CXCL8 and CXCL12 have also been reported 
to induce the recruitment of MDSCs into the TME [60]. As one of the major cellular components 
of the TME, MDSCs exert immunosuppressive activities mainly by the upregulation of inhibitory 
PD-L1 on the surface, release of immunosuppressive cytokines such as transforming growth factor 
(TGF-β) and IL-10, and production of chemokines (e.g. CCL4 and CCL5) for Tregs into tumors 
[61]. As MDSCs are phenotypically and morphologically similar to monocytes and neutrophils, 
therapeutic strategies that can specifically target MDSCs may provide better therapeutic benefits 
(see review in [60, 61]).  
Macrophage type 2 (M2) cells: In contrast to M1 cells that act preferentially in pro-
inflammatory responses and antitumor cytotoxic function, M2 counterparts exert anti-
inflammatory and tissue remodeling/regenerative roles [62]. MDSCs may drive TAMs towards 
the M2 phenotype by increasing the secretion of IL-10 and alleviating the production of IL-12 
[49]. In addition, when TAMs are infiltrated into tumors, they are preferentially differentiated into 
M2 cells under the stimulation of cytokines (e.g. IL-4, IL-13, IL-21 and IL-33) and chemokines 
(e.g. CCL2 and CXCL4) [49]. The M2 subclass is functionally characterized by the 
immunosuppression and the promotion of tissue remodeling (e.g. angiogenesis). For example, M2 
macrophages express different chemokines such as CCL17, CCL22 and CCL24, and these 
chemokine receptors are present on Th2 and Treg cells [49, 62]. As such, the release of M2 
chemokines can lead to the recruitment of immunosuppressive cells into tumors. The activation of 
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M2 cells exerts inhibitory activity against DCs and T cells by releasing suppressive cytokines (e.g. 
IL-10 and TGF-β) [63], produces inhibitory metabolites for T cell suppression/anergy/death by 
triggering IDO-1 mediated pathway [64], and induces immune tolerance by expressing checkpoint 
molecules (e.g. PD-L1 and CD47) [65]. M2 macrophages also facilitate neovascularization by the 
release of pro-angiogenic mediators such as IL-8, vascular endothelial growth factor (VEGF), 
basic fibroblast growth factor (bFGF), and epidermal growth factor (EGF) [66]. Recently, the 
inhibition of TAM recruitment and depletion of M2 macrophages have provided therapeutic 
opportunities to restrain tumor growth and metastasis [67]. In addition, due to the controversial 
(supportive and inhibitory) role of TAMs, strategies reprogramming the phenotype from M2 to 
M1 to rescue antitumor immunity have presented significant antitumor potential [62]. 
Regulatory T cells (Tregs): As a subtype of T cells, Tregs play important roles in the 
maintenance of immunological tolerance in the periphery (e.g. autoimmune diseases) by 
suppressing the host immunity against self- and nonself-antigens [68]. The most physiologically 
relevant Tregs are characterized by the expression of surface markers CD4/CD25 and transcription 
factor Forkhead box protein 3 (FoxP3) [69]. Accumulating evidence indicates that an elevated 
number of CD4+CD25+FoxP3+ Tregs are infiltrated into tumors, and their abundant presence is 
considered a major hurdle to effective immunotherapy [70]. It has been reported that Tregs in 
patients with tumors, as compared to those in healthy populations, are often evident with high 
expression of chemokine receptors such as CCR4, CCR5 and CXCR4, and the corresponding 
chemokines derived from the TME can facilitate the infiltration of Tregs into tumors [71]. Treg-
mediated suppressive mechanisms mainly include: 1) they scarcely produce IL-2 but express the 
high-affinity IL-2 receptor α chain (CD25) to deprive this cytokine from the neigbour, which may 
limit the activation and proliferation of effector T cells [72]; 2) CTLA-4 expressed on Tregs has 
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higher affinity for CD80 and CD86 (co-stimulatory molecules) on DCs than CD28 expressed on 
T cells does (the interaction between CD28 and CD80/CD86 provides co-stimulatory signals 
required for the activation and survival of T cells), thus hindering co-stimulation of T cells [73]. 
In addition, the binding of CTLA-4 with CD80/CD86 may downregulate the expression of these 
co-stimulatory molecules, further causing the inactivation of T cells [74]; 3) Tregs can produce 
immunosuppressive cytokines (e.g. IL-10 and TGF-β) to skew the function of DCs and T cells, 
and may even cause direct killing of these immunostimulatory cells by secreting granzymes and 
perforin [75]. Recent progress in tumor immunotherapy targeting Treg-mediated 
immunosuppressive mechanisms holds great promise for cancer patients [76].  
Regulatory B cells (Bregs): As discussed above, B cells are subveted toward Bregs inside 
the TME, which is accomplished by pathways of TLR, CD40/CD40L, B-cell activating factor 
(BAFF), BCR, and CD80/CD86 [77]. Bregs negatively regulate antitumor immunity through 
different mechanisms: 1) they produce immunosuppressive mediators such as cytokines (e.g. IL-
10, TGF-β and IL-35) and IDO-1, which can suppress the proliferation and activation of T and NK 
cells [41]; 2) Bregs inactivate these immunostimulatory cells by expressing immune checkpoints 
(e.g. PD-L1) [78]; 3) when Bregs express the death-inducing molecule Fas ligand (FASL), they 
will induce the apoptosis of effector T cells [79]; 4) Bregs promote tumor progression by secreting 
TGF-β for epithelial-mesenchymal transition (EMT) [80]. In addition, the expression of 
suppressive markers (e.g. FoxP3 and CTLA-4) on Tregs can be promoted by Bregs by cell-to-cell 
contact [81]. Therefore, strategies used to target or reshape Bregs may provide therapeutic 
potential for rescuing antitumor immunotherapy. 
Stromal cells: As important cell types inside the TME, stromal cells (e.g. fibroblasts, 
vascular endothelial cells and pericytes) usually facilitate the development and maintenance of 
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tumors by supporting tumor cells, remodeling ECM, and promoting angiogenesis [82]. Recently, 
accumulating evidence has indicated that stromal cells also play immunosuppressive roles within 
the TME [82]. As one of the prominent stromal cells inside the TME, tumor-associated fibroblasts 
(TAFs) are composed of heterogeneous subtypes that are derived from different cellular origins 
(e.g. local fibroblasts and mesenchymal stem cells) [83]. The fibroblasts are usually quiescent in 
healthy tissues and early-stage cancers, however, they become activated and are turned into TAFs 
following a serial of physiological and biochemical changes during tumor progression (see review 
in [84]). TAFs are involved in ECM remodeling, tumor immunity, angiogenesis, and cancer cell 
proliferation and metastasis, which have previously been reviewed [85, 86]. In addition, the highly 
heterogeneous tumor vasculature is also a key component associated with the TME in many solid 
tumors, which result in abnormal blood flow into under-perfused tumor areas [87]. Due to the lack 
of functional intratumor lymphatic vessels, the elevated interstitial fluid pressure disrupts the 
transport of therapeutic agents to the TME [87]. The tumor blood and lymphatic vascular networks 
can hinder immunosurveillance mechanisms and suppress antitumor immunity, which have been 
discussed elsewhere [88]. Therefore, novel therapeutic strategies used to remodel these stromal 
cells also hold great promise for overcoming immunotherapy resistance [88].  
Recently, the reprogramming of immunoregulatory cells has been achieved using 
nanomaterial-based approaches, which can profoundly improve immune therapy against cancers. 
The methods of engineering nanomaterial-based approaches for targeted modulation of 
immunoregulatory cells have been extensively reviewed by Shi et al. [89] and Yu et al. [90], 
demonstrating the significant promise of NPs for enhancing the efficacy of current 
immunotherapies (see reviews for more details). It is known that the reprogramming of one single 
cell type is normally not sufficient to achieve antitumor efficacy, whereas the modulation of 
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different cell populations simultaneously may lead to satisfactory therapeutic outcome. Notably, 
the concepts of immunoregulatory cells still remain debatable due to controversial issues such as 
the origin and nature of these cells and their distinctive biological roles at different stages of cancer 
(so called the double-edged sword) [91]. Therefore, technologies that precisely discriminate these 
cells are urgently required to solve these controversies, obtain a deeper insight into the definition 
of distinctive cell types, and confirm therapeutic targets for nanomaterial-based 
immunotherapeutics (nanoimmunotherapeutics). 
3.3 Technologies for characterization and quantification of immunoregulatory cells 
As described above, the TME is composed of a heterogeneous population of tumor cells 
and distinct resident/infiltrating non-tumor cells such as immune cells, fibroblasts, endothelial 
cells, pericytes [92], and adipocytes [93]. Tumorigenesis is profoundly affected by reciprocal 
interactions between these cells through cell-to-cell contact, secreted factors, and ECM 
proteins/peptides [7]. Recent studies have suggested the impact of resident/tumor-infiltrating host 
cells on cancer prognosis and clinical outcome of immune-based therapies [10], indicating the 
importance of immunoregulatory cells in the TME. In addition, a deeper analysis of complexity 
and diversity of immunoregulatory cells may facilitate a better understanding of how these cells 
affect the TME, which will enable the prediction of therapeutic responsiveness and reveal new 
therapeutic targets. The commonly used technologies to identify and quantify immunoregulatory 
cells in terms of phenotypic and functional analyses are selectively discussed in here. 
Analysis of immunological phenotypes: As shown in Table 1, immunoregulatory cells 
represent a heterogeneous population, which differ in their cell surface antigens and intracellular 
markers in a spatiotemporal manner (e.g. early stage v.s. late stage and tumor-infiltrating v.s. blood 
circultating). These molecules can be characterized and quantified using antibody-based imaging 
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and cellular phenotypic techniques, such as immunohistochemical (IHC) staining assay [94], 
immunofluorescent (IF) microscopy [95], and flow cytometry [96]. The IHC- and IF-based 
analyses can be used to study the expression and location of antigens of interest from in vitro, in 
vivo and clinical samples. These techniques are also useful to investigate the trafficking, 
internalization, and recycling of surface antigens/receptors. In addition, the co-localization of cells 
with cells may also be assessed using these technologies. However, it is worth noting that IHC- 
and IF-based analyses are often associated with practical pitfalls [97] and subjective interpretation 
[94], therefore, experienced researchers and qualified pathologists are required to perform 
experimental procedures and data analyses. Also, it is difficult to track different antigens inside 
individual cells from the same slice of a sample using IHC- and IF-based analyses. In contrast to 
these techniques, flow cytometry may provide greater sensitivity and specificity for single cells 
[96], and therefore has long been considered a preferred analysis method in the field of 
immunology. Recently, the incorporation of imaging, spectrometric and cytometric technologies 
including the mass spectrometry IHC (MSIHC) [98], quantitative immunofluorescence (QIF) [99], 
imaging flow cytometry (IFC) [100] and mass cytometry (flow cytometry coupled with mass 
spectroscopy) [101], may provide more reliable and reproducible antibody-based technologies for 
characterization and quantification of immunoregulatory cells. In addition, clinical imaging 
modalities such as positron emission tomography (PET) and magnetic resonance imaging (MRI) 
have also been used for the detection of tumor-associated immune cells (e.g. macrophages) in 
animal models and patients [102].  
It is worth noting that although the imaging and cellular phenotypic technologies are widely 
applied, they can only provide partial information about the “immune fingerprint” due to their 
limited ability for characterizing a tremendous number of immune subpopulations in tumors. In 
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recent years, bioinformatics, which is defined as a subject that combines biology, computer 
science, information engineering and mathematics/statistics, has become one of fastest growing 
technologies in the fields of biology and medicine [103]. Bioinformatics has earned its place as a 
high-throughput computational tool to analyze large collections of biological data (e.g. DNA/RNA 
sequences, protein samples and cell populations) in a whole genome pattern [104]. This technique 
can be used for discovering novel candidate genes/proteins underlying disease progression as well 
as for identifying new therapeutic targets [105]. Computational genomic tools, which are 
categorized into two methods namely gene set enrichment analysis (GSEA) and deconvolution, 
can be used to comprehensively analyze immunophenotype in the TME [106]. Both methods are 
relied on a matrix of expression profiles (e.g. gene expression profiles, DNA methylation profiles 
or IHC profiles) for individual cell populations, and the detail has been substantially reviewed 
[106, 107]. Among these single-cell analyses, single-cell RNA sequencing (scRNA-seq) has 
received increasing attention due to its ability to uncover complex and rare cell populations, reveal 
relationships between genes, and delineate distinct cell lineages during early development [108]. 
By means of isolating individual cells, obtaining the transcripts, and establishing sequencing 
libraries (the transcripts are mapped to single cells) [109], scRNA-seq also allows researchers to 
assess highly diverse immune cell populations in healthy and malignant sites/states [110]. For 
example, Szabo et al. utilized scRNA-seq to define the heterogeneity of T cells isolated from the 
blood, bone marrow, lungs and lymph nodes from healthy donors [111]. By analysis of over 50,000 
resting and activated T cells throughout these tissues, authors described T cell signatures (e.g. 
distinct effector states for CD8+ T cells and an interferon-response state for CD4+ T cells) and 
generated a healthy baseline dataset [111]. Subsequently, the comparison between the scRNA-seq 
profiles of tumor-associated T cells published by others and the reference map of healthy dataset 
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generated by authors revealed the predominant activities of T cells at different tumor sites, 
providing insights of how to define the origin, composition and function of immune cells in 
malignant diseases [111]. Therefore, it is expected that the heterogeneity and dynamics of immune 
cell infiltrates in tumors can also be characterized using scRNA-seq in response to NP-based 
immunotherapy. 
In addition to characterization and quantification between immunoregulatory cells, a 
variety of computational methods and software tools (see guidelines in [106, 107]) may be used to 
unravel tumor-immune cell interactions for better understanding of tumor immunology, predict 
neoantigens for therapeutic cancer vaccination, and determine mechanistic principles for 
combination treatment with synergistic effects [112].  
Analysis of immunological functions: As shown in Figure 1.1, immunoregulatory cells 
produce a variety of stimulatory and suppressive cytokines and chemokines to manipulate the 
crosstalk between cancer cells and the host immune system. In order to accurately detect and 
quantitate the immune responses within the TME, a number of techniques such as real-time 
quantitative polymerase chain reaction (qPCR), enzyme-linked immunosorbent assay (ELISA), 
enzyme-linked immunospot (ELISPOT) and flow cytometry, can be carried out to evaluate the in 
vitro and in vivo expression of cytokines and chemokines. The level of cytokine mRNA transcripts 
from in vitro and in vivo models can be measured using qPCR. The in vitro and in vivo release of 
cytokines by immune cells may be assessed by either quantifying bulk cytokine production using 
ELISA [113] or measuring individual cytokine-producing cells using ELISPOT [114]. Detection 
of intracellular cytokines from tumor tissues, lymph nodes and peripheral blood may also be 
carried out using flow cytometry [115]; for example, CD8 and IFN-γ double-positive T cells are 
considered effector CTLs [116]. In addition, immunostimulatory cells will proliferate in response 
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to successful immune-based therapies, whereas immunosuppressive counterparts will decline. The 
proliferative states of T cells may be evaluated by flow cytometry according to the level of 
proliferation markers (e.g. Ki67) and the intensity of proliferation tracking fluorescent dyes (e.g. 
carboxyfluorescein succinimidyl ester (CFSE)) [117].  
It is worth noting that these phenotypic and functional analysis technologies have certain 
limitations (see discussion in [94, 97, 107]), therefore, it is critical to understand their ability and 
availability, in order to assist in the selection of appropriate and accurate ones. In fact, a 
combination of these techniques is preferred to provide high-accuracy for characterization and 
quantification of immunoregulatory cells. 
4. Recent Advances in Nanomaterial-Based Strategies for Cancer Immunotherapy via 
Modulation of TME 
The TME, which contains immunosuppressive cells and soluble signaling molecules, 
disorganized blood vessels and the dense ECM, is highly resistant to currently available immune-
based therapies. Recent advances in the fields of nanotechnology and biomedical engineering 
provide great potential for the delivery of immunoregulatory agents to modulate the TME 
systemically (lymph nodes) and locally (tumors) [118], in order to restore the cancer-immunity 
cycle (Figure 1.1). Nanomaterial-based delivery strategies designed for immunotherapy, when 
applied alone or in combination with chemotherapy, gene therapy, phototherapy and radiotherapy, 
have profoundly revolutionized cancer therapy [119]. In vivo studies using a variety of 
immunotherapeutics are summarized in Table 2 according to the material type, nanoformulation 
strategy, and immunologic modulation. In this section, selected recent examples will be discussed 




















LPD with PD-L1 trap for colorectal 
cancer  




LPD with pLPS trap for colorectal 
cancer 
DC, CD8+ and CD4+ T, M1/M2 
 
Treg, MDSC  
[120] 
LPD with IL-10 and CXCL12 traps 
for pancreatic cancer 
DC, CD8+ T, NK  
M2, MDSC  
[121] 
LCP with pRLN for liver cancer  DC, CD8+ and CD4+ T, M1/M2 
 
Treg, TAF, MDSC  
[122] 
LCP with CXCL12 trap for liver 
metastasis 
CD8+ T  
Treg, MDSC, TAF  
[123] 
LCP with BRAF peptide for 
melanoma  
DC, CD8+ T, M1/M2  
Treg  
[124] 
Liposome with HDZ to increase NP 
tumor penetration in desmoplastic 
melanoma 
DC, CD8+ and CD4+ T, NK, 
M1/M2  
MDSC, TAF  
[125] 
Lipid NP with OxP and DHA for 
colorectal cancer 








PMP/OVA/siRNA nanovaccine for 
melanom 
DC, CD8+ and CD4+ T  
Treg, MDSC  
[127] 
AC-NP for melanoma DC, CD8+ T, CD8+ T/Treg, 
CD4+ T/Treg  
[128] 
PLGA-R847@Cat NP enhanced 
radiotherapy for colon cancer 
DC, CD8+ and CD4+ T  










NanoNO to normalize tumor 
vasculature for liver cancer 
CD8+ and CD4+ T, M1  
TAF, M2  
[130] 
TPGS-based nanoemulsion with 
quercetin and alantolactone for 
colorectal cancer 
DC, NK, CD8+ and CD4+ T  
Treg, MDSC  
[131] 
DINP with aPD1 and aOX40 for 
melanoma 
CD8+ and memory T  [132] 
BCPN with oxaliplatin prodrug and 
NLG919 for colorectal and breast 
cancers 
DC, CD8+ T  
Treg  
[133] 
H1-NB NP with OVA for melanoma DC, CD8+ T  [134] 
Cellax NP with DTX for metastatic 
pancreatic cancer 











CaCO3 NP gel with aPD-1 and 
zebularine for melanoma 
DC, CD8+ and CD4+ T  
MDSC  
[136] 
CaCO3 NP gel with aCD47 for 
melanoma 
CD8+ T, M1  
Treg, M2, MDSC  
[137] 
H-MnO2 NP for TME modulation for 
triple negative breast cancer 
CD8+ T, M1  
Treg, M2  
[138] 
Fe3O4-ZnO nanovaccines for 
colorectal cancer 
DC, CD8+ and CD4+ T  [139] 
Hollow mesoporous silica 
nanosphere as cancer 
immunoadjuvant for lung cancer  
CD8+ and CD4+ T  [140] 
AuNP-DNA photothermal 
immunotherapy for tumor 
DC, HSP70  [141] 
MoS2-PEG-CpG for photothermal 
cancer immunotherapy 
DC  [142] 
 
 Erythrocyte membrane coated NP as 
cancer vaccine for melanoma 
DC, CD8+ T  [143] 
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Table 2. A brief summary of in vivo studies on delivery of immunoregulatory agents using 
nanoparticles and natural carriers, including material types, nanoformulation strategy, and 
immunologic modulation. ( = upregulation,  = downregulation) 
 
4.1. Promoting immunostimulatory effects to “fuel the engine”  
Methods for the initiation of antitumor immunity including the antigen release, 
presentation and T cell priming/activation (step 1 to step 3, Figure 1.1) have been substantially 
studied (Figure 1.2). Several nanovaccines are currently investigated in clinical trials for certain 
solid tumors [89, 90]. Recently, biomimetic nanovaccines have been developed for overcoming 






Cancer cell membrane-coated NP as 
cancer vaccine for melanoma 
DC, CD8+ T  [144] 
Cancer cell membrane-coated NP for 
anticancer vaccine for melanoma 
DC, CD8+ T  [145] 
NP coated bacterial as oral DNA 
vaccines for melanoma 










Lipoprotein NP for antigen delivery 
for colorectal cancer and melanoma 
CD8+ , CD4+ and memory T  [147] 
Lipoprotein NP with DOX for 
colorectal cancer 
DC, CD8+ T  [148] 
T cells conjugated with IL-15 and 
IL-21 loaded NP for melanoma 
CD8+, CD4+ and memory T  [149] 
T cells with amphiphilic ligands for 
melanoma and glioma 
CD8+ and CD4+ T  [150] 
T cells conjugated with NSC-87877 
loaded NP for prostate cancer 
CD8+ T  [151] 
Platelets loaded aPD-L1 for 
melanoma and triple negative breast 
cancer  
CD8+ and CD4+ T  
Treg  
[152] 
Photothermal therapy for tumor 
infiltration and antitumor activity of 
CAR T Cells in melanoma 
CD8+ and CD4+ T  [153] 
24 
 
targeted delivery, and long-term release [120-122]. The modification of NPs with peptides, 
proteins and antibodies has also been achieved to produce biomimetic nanovaccines with the 
enhanced potency, which may allow better reprogramming of immune responses [120-122]. The 
approaches of engineering biomimetic nanovaccines and their application in remodeling the TME 
for cancer immunotherapy have been extensively reviewed (see more details in [120-123]). 
 
Figure 1.2. Development of nanovaccines for promoting immunostimulatory effects to “fuel the engine” 
(A) LCP-based delivery of mRNA vaccine for an enhanced immune response against melanoma. Adapted with 
permission from [160], copyright 2017 Elsevier. (B) Albumin-mediated enhanced CAR-T cell activity for solid 
tumors. Adapted with permission from [150], copyright 2019 American Association for the Advancement of 
Science (C) Cancer cell membrane-coated adjuvant NPs with mannose modification for anticancer vaccination. 
Adapted with permission from [144], copyright 2018 American Chemical Society. (D) Erythrocyte membrane-
coated NPs as vaccine for antitumor immunity against melanoma. Adapted with permission from [143], copyright 
2015 American Chemical Society. 
Nanomaterials alone or when formulated with antigens in a form as DNA, RNA or peptides 
can be designed for delivery into APCs in the lymph nodes, which boost T cell priming and 
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activation for antitumor immunity [124, 125]. Recently, Wang et al. have developed a mannose-
targeted PEGylated lipid-coated calcium phosphate (LCP) NP for co-delivery of mRNA (encoding 
tyrosinase-related protein 2 (TRP2), a melanoma-associated antigen) and siRNA (targeting PD-L1 
mRNA) to DCs in the lymph nodes [126]. The LCP-mediated expression of TRP2 in DCs elicited 
a robust antigen-specific CTL response as well as the production of serum immunoglobulin G 
against the full-length TRP2 protein in mice with melanoma [126]. In addition, the PD-L1 
expression in DCs was significantly downregulated by LCP-mediated siRNA, resulting in 
enhancement of T cell activation and proliferation. Consequently, this LCP nanovaccine 
remarkably inhibited tumor growth and metastasis [126].  
It has been recently reported that stimulator of interferon genes (STING, a signaling 
molecule) plays a significant role in the regulation of intracellular DNA-mediated IFN-dependent 
innate immunity [127], demonstrating the potential of STING-mediated cancer immunotherapy. 
The details of molecular pathways associated with STING, STING agonists/inhibitors, and how 
to activate STING using nanomaterial-based strategies for cancer immunotherapy have been 
substantially summarized in [128, 129]. Recently, Luo et al. demonstrated a nanovaccine by 
physical mixture of an antigen and a synthetic polymeric NP (termed PC7A NP) [130]. In this 
study, the delivery of tumor antigens to APCs in the draining lymph nodes was achieved using 
PC7A NP, resulting in the surface presentation while simultaneously activating STING-dependent 
type I interferon-stimulated genes [130]. As a result, this nanovaccine significantly inhibited the 
tumor growth in mice with melanoma, colon cancer, and human papilloma virus-E6/E7 cancer 
[130]. In addition, cyclic dinucleotide (CDN) agonists of STING have demonstrated a promising 
role in the activation of tumor immunogenicity [131]. However, the therapeutic efficacy of CDNs, 
due to the hydrophilicity, negative charge and sensitivity to enzymatic degradation, is limited by 
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in vivo delivery barriers. Therefore, Shae and co-workers developed a polymeric NP 
(polymersome) for enhanced intracellular delivery of 2’3’ cyclic guanosine monophosphate-
adenosine monophosphate (cGAMP, the endogenous ligand for STING) [132]. The resultant 
formulation (termed STING-NPs) significantly increased the cytosolic activity of cGAMP, 
promoted the STING signaling in the TME and sentinel lymph nodes, and turned 
immunosuppressive tumors into immunogenic [132]. Consequently, the therapeutic outcomes 
including the suppression of tumor growth, long-term survival, and induction of immunological 
memory were successfully achieved by STING-NPs in mice with melanoma [132]. 
In addition to design of nanovaccines for delivery into APCs in lymph nodes, NPs 
containing certain therapeutic agents may convert cancer cells into their own vaccine. When tumor 
cells undergo immunogenic cell death (ICD, also known as immunogenic apoptosis), the DAMPs 
released by dying tumor cells, which mainly include the exposure of calreticulin (CRT) onto cell 
surface, secretion of adenosine triphosphate (ATP), and release of high mobility group protein B1 
(HMGB1), will activate DCs [133]. Consequently, ICD makes the dying cancer cells operate as a 
vaccine that can trigger a tumor-specific immune response [133]. ICD can be induced by certain 
chemotherapeutic drugs (e.g. anthracyclines, mitoxantrone, oxaliplatin, and bortezomib) [134], 
physical treatments (e.g. UV irradiation and photodynamic therapy) [135], and oncolytic viruses 
[136]. In addition, the details of ICD-associated signaling pathways, the ICD inducers, and NP-
based ICD-mediated cancer immune therapy have been extensively described in [134, 137, 138]. 
Recently, Liu and co-workers have developed an amino ethylanisamide (AEAA, targeting Sigma-
1 receptors overexpressed on cancers [139])-targeted PEGylated polymeric NP for co-delivery of 
mitoxantrone (the ICD inducer) and celastrol (a pentacyclic triterpene extracted from Tripterygium 
wilfordii) in mice with desmoplastic melanoma. Consequently, the resultant formulation 
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containing two agents at the optimal ratio significantly induced ICD-mediated immunotherapeutic 
effects, reprogram the fibrotic and immunosuppressive TME, and promote the progression-free 
survival and sustained immunosurveillance in diseased mice [140]. 
4.2. Overcoming immunosuppressive barriers to “release the brake”  
The efficacy of antitumor immunity including the trafficking/infiltration of T cells, 
recognition of tumor cells by T cells and killing of tumor cells (step 4 to step 7, Figure 1.1) is 
significantly dampened by the immunosuppressive TME. Therefore, approaches used to overcome 
such immune tolerance have been extensively investigated (Figure 1.3). Recent advances in 
nanoengineered strategies for delivery of checkpoint inhibitors have been reviewed [141]. These 
NP-based approaches enable the selective delivery of checkpoint inhibitors into tumors, which can 
reduce immune-related toxic issues. Consequently, they significantly reprogram 
immunosuppressive cells and improve the activity and persistence of effectors T cells. In addition, 
a number of NP-based delivery approaches have been recently developed for delivery of 
therapeutic components (e.g. chemotherapeutics, antibody and siRNA) to target 
immunosuppressive soluble mediators such as TGF‐β, IDO, COX‐2 and epidermal growth factor 
receptor (EGFR), which can significantly remodel the suppressive TME and restore the antitumor 




Figure 1.3. Development of nanoimmunotherapeutics for overcoming immunosuppressive barriers to 
“releasing the brake”. 
(A) Local blockade of IL-10 and CXCL 12 using LPD for antitumor response for pancreatic cancer. Adapted with 
permission from [121], copyright 2018 American Chemical Society. (B) Inhibiting PI3 kinase-γ using AEAA-
targeted PLGA in both myeloid and plasma cells to remodel the suppressive TME in pancreatic cancer. Adapted 
with permission from [139], copyright 2019 Elsevier. (C) Liposome-mediated delivery of vasodilator hydralazine 
for nanoparticle penetration in advanced desmoplastic melanoma. Adapted with permission from [142], copyright 
2019 American Chemical Society. (D) Immunotherapeutic strategy for melanoma via dual-targeting NPs delivering 
siRNA to TAMs. Adapted with permission from [143], copyright 2017 American Chemical Society 
 
 
TAMs have recently become a promising therapeutic target; however, it is still challenging 
to deliver therapeutic agents to them. Recently, a liposomal NP has been developed with the 
modification of α-peptide (a scavenger receptor B type 1 (SR-B1) targeting peptide) and M2pep 
(an M2 macrophage binding peptide) [143]. Following intravenous (i.v.) injection this dual-
targeted NP demonstrated higher binding affinity to M2-like TAMs than to tissue-resident 
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macrophages in healthy tissues. As a result, the inhibition of survival signals in M2-like 
macrophages as well as the depletion of this cell type from melanoma were achieved using this 
dual-targeted NP containing siRNA against colony stimulating factor-1 receptor (CSF-1R), which 
was observed along with the increase of immunogenic cytokines (IL-12 and IFN-γ) and reduction 
of immunosuppressive cytokines (IL-10 and TGF-β) [143]. In addition, Rodell et al. developed a 
β-cyclodextrin NP (CDNP) for delivery of R848 (an agonist of TLR7 and TLR8) in a range of 
tumor models in mice [144]. As a result, CDNP-R848 significantly altered the TAMs toward the 
M1 phenotype, which slowed down tumor growth and protected mice against tumor rechallenge 
[144]. More importantly, improved antitumor immune responses were achieved by CDNP-R848 
when applied in combination with anti-PD-1 therapy, confirming the potential of NP-based 
strategies to effectively remodel TAMs for cancer immunotherapy [144]. 
Stromal cells as one of the key cellular components in the TME usually facilitate the 
development and maintenance of tumors by supporting tumor cells, remodeling ECM, and 
promoting angiogenesis [82]. It has been reported that the development of liver metastasis is often 
associated with activated hepatic stellate cell (aHSC)-mediated liver fibrosis, and the relaxin 
(RLN, an anti-fibrotic peptide) can deactivate aHSCs and therefore resolve liver fibrosis [145]. 
Therefore, an AEAA-targeted PEGylated LCP NP containing the RLN plasmid was developed by 
Hu and co-workers to target cancer cells and aHSCs within the metastatic lesion and use them as 
an in situ factory for the production of RLN protein. Consequently, the stromal microenvironment 
in liver metastases was effectively reversed by LCP-mediated expression of RLN protein, which 
significantly inhibited metastatic progression and prolonged the survival of animals, accompanied 
with the upregulation of immunogenic cells/cytokines and downregulation of immunosuppressive 
counterparts [145].  
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Although NPs may take advantage of the enhanced permeability and retention (EPR) effect 
for tumor accumulation [146], the elevated interstitial fluid pressure, high density of ECM and 
disorganized blood vessels (particularly in desmoplastic tumors) cause significant hurdles for 
particle penetration. To address these issues, Chen and colleagues developed a hydralazine (HDZ, 
a routine medication used to treat high blood pressure and heart failure)-containing liposomal NP 
to reshape tumor blood vasculature in advanced desmoplastic melanoma [142]. The i.v. injection 
of HDZ-liposome favorably modulated the vascular dilation, tumor hypoxia, and tumor 
permeability, which were accompanied with the TME modulation (Figure 1.3). As a result, the 
HDZ-liposome significantly improved the therapeutic efficacy of liposomal doxorubicin as the 
second-wave treatment in mice with tumor size over 400 mm3 [142]. In addition, it has been 
reported that high concentration of perivascular nitric oxide (NO) can facilitate tumor vascular 
normalization and further the chemotherapy efficacy [147]. Despite the promising anticancer 
effect, the clinical application of NO is limited by the short half-life, low bioavailability, and poor 
tumor targeting behavior [147]. Recently, Sung et al. have developed a poly(lactic-co-glycolic 
acid) (PLGA)-based delivery system (NanoNO) containing dinitrosyl iron complex (DNIC, the 
NO donor) [147]. In murine hepatocellular carcinoma model, NanoNO was able to provide 
sustained NO release into tumors, which resulted in effective normalization of tumor vasculature 
and improve the delivery of follow-up chemotherapy for the suppression of primary tumors and 
metastases [147]. Immunological analyses revealed that NanoNO at a lower dose could reprogram 
the immunosuppressive TME therefore improving the anticancer efficacy [147].  
4.3. The combination therapy  
Schemes that simultaneously target stimulatory and inhibitory mechanisms potentially 
provide synergistic antitumor immunotherapeutic effectiveness (Figure 1.4). It has been reported 
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that the blockage of immune checkpoint molecules using systemically administrated mAbs may 
reverse the immune tolerance, but autoimmune-like side effects are unavoidable for healthy tissues 
or organs [148]. Alternatively, local delivery of immune checkpoint inhibitors in the TME may 
alleviate the immune-related adverse effects (irAEs). Therefore, Song and colleagues developed 
an AEAA-targeted lipid-protamine-DNA (LPD) NP for delivery of plasmid encoded with PD-L1 
trap (a small antibody-like fusion protein targeting PD-L1) in mice with colorectal cancer. 
Consequently, the expression of PD-L1 trap by LPD in tumors led to a synergistic chemo-
immunotherapeutic outcome in combination with oxaliplatin (OxP)-mediated ICD effects, 
resulting in longer animal survival time and lower level of irAEs, in comparison with free PD-L1 
mAb and OxP [149]. 
 
Figure 1.4. Development of nanoimmunotherapeutics for combination therapy. 
(A) NP-mediated co-delivery of mitoxantrone (MIT) and celastrol (CEL) to induce chemo-immunotherapy for 
cancer inhibition and tumor dormancy in desmoplastic melanoma. Adapted with permission from [140], copyright 
2018 American Chemical Society. (B) NP-based co-delivery of Quercetin (Q) and Alantolactone (A) for antitumor 
responses through synergistic ICD. Adapted with permission from [131], copyright 2019 American Chemical 
Society. (C) Synergistic and low adverse effect cancer immunotherapy by LPD-mediated immunogenic 
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chemotherapy and locally expressed PD-L1 trap in combination with oxaliplatin for colorectal cancer. Adapted with 
permission from [149], copyright 2018 Nature Publishing Group. (D) LCP-mediated relaxin gene delivery for 
synergistic effect with checkpoint inhibition in liver metastasis. Adapted with permission from [145], copyright 
2019 Nature Publishing Group. 
It is known that IDO‐1 is one of tryptophan catabolic enzymes that can facilitate the 
conversion of tryptophan (Trp) to kynurenine (Kyn) [150]. The downregulation of Trp can 
suppress the proliferation and activity of CTLs and NKs, and the upregulation of Kyn can activate 
Tregs and MDSCs [151]. Therefore, approaches against IDO-1 hold great promises for tumor 
immunotherapy. Indeed, the combination immunotherapy has been achieved using the co-delivery 
of IDO-1 inhibitor and immune checkpoint inhibitor [152]. In addition, it has been reported that 
IFN-γ released by ICD-mediated CTLs can positively regulate tumor immunogenicity, but may 
also cause the production of IDO-1, which dampen the immunotherapeutic efficacy [153]. To 
address such paradox, Feng et al. developed an amphiphilic polymeric NP for co-delivery of OxP 
prodrug and NLG919 (an IDO-1 inhibitor) to induce OxP-mediated ICD effects and reverse IDO-
1 mediated immunosuppression, respectively [154]. Consequently, the resultant nanoformulation 
(BCPN) could achieve significantly better tumor inhibition at primary and metastatic sites than the 
combination of free OxP and NLG919 [154]. 
In addition, a light-sensitive in situ gelation system was reported by Meng et al. for the 
combination of photodynamic therapy and immunotherapy [155]. In this study, the photosensitizer 
(Chlorin e6, Ce6) modified-catalase (CAT, an enzyme triggers the rapid decomposition of H2O2) 
was conjugated with poly(ethylene glycol) double acrylate (PEGDA) to form Ce6-CAT-PEGDA. 
Subsequently, the Ce6-CAT-PEGDA was mixed with imiquimod (R837)-loaded PLGA NPs 
(RPNPs, the immune adjuvant), forming a polymeric matrix (Ce6-CAT-PEGDA-RPNPs) [155]. 
When locally applied to tumors and exposed under 660 nm red light, Ce6-CAT-PEGDA-RPNPs 
significantly reversed the immunosuppressive TME by the production of O2 that can relieve the 
tumor hypoxia [155]. Consequently, the photodynamic therapy-mediated ICD together with 
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immune adjuvant could mediate a significantly stronger “abscopal effect” for tumor inhibition at 
primary and distant sites [155]. 
5. Conclusions  
In recent years, an improved understanding of cancer biology [156] and the discovery of 
cellular and molecular mechanisms for innate and adaptive immunologic responses [157] have 
significantly revolutionized the fields of cancer immunology and immunotherapy. These have 
remarkably encouraged researchers to investigate the possibility of restoring the cancer-immunity 
cycle using nanomaterial-based immunotherapeutics (nanoimmunotherapeutics) [158-160]. 
Several studies of NP-based cancer immunotherapy are currently undertaken in clinical trials (see 
the summaries in [89, 90]). Despite the potential of nanoimmunotherapeutics for solid tumors [90], 
none of them have reached the clinic for patients. One major reason for the lack of clinical 
translation is the presence of the immunosuppressive TME. As shown in Table 2, substantial 
studies have been undertaken for investigating the capacity and availability of NP-based delivery 
of immunoregulatory agents to systemically and locally modulate the suppressive milieu within 
the TME. These works provide proof of concept for NP-based TME-modulating methods and 
illustrate the potential of nanoimmunotherapeutics to advance the “fuel the engine, release the 
brake” rules (see reviews in  [141, 161-163]). 
In addition, one of the major remaining challenges associated with clinical translation of 
nanoimmunotherapeutics (nanomedicine as well) is still the lack of efficient, safe and widely 
applied delivery strategies to facilitate the transport of therapeutic agents to tumor sites following 
systemic administration [164]. Although NPs may accumulate into tumors following the EPR 
effect, the delivery efficacy is extremely low [165]. In addition, a large number of intratumoral 
NPs may be either isolated by the ECM or taken up by non-specific cells. The high density of 
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ECM and tortuous blood vessels (particularly in desmoplastic tumors) may be overcome by NPs 
containing a variety of TME modulators [142, 145, 147, 166, 167], which relieve the harsh niches 
associated with the failure of drug delivery and enhance the follow-up treatment of targeted 
nanoimmunotherapeutics that act specifically in cells of interest.  
In addition, it should be borne in mind that complicated modifications of nanomaterials, 
which is hoped to achieve multifunctional delivery formulations with stabilizing groups, targeting 
ligands and bioresponsive linkers, may complicate the large-scale and reproducible production. In 
addition, such extensive modifications may also cause unexpected toxicity. Therefore, further 
investigation must be performed to keep balance between the therapeutic benefit, the complexity 
of formulation preparation/scale-up and the risk of toxicity before nanoimmunotherapeutics can 
be satisfactorily applied for cancer patients. 
Therefore, this thesis study aims to design simple formulations with clinical translational 
potential and scale-up capabilities to deliver immuno-regulatory therapeutic agents to locally 
modulate the suppressive TME in solid tumor. We particularly emphasis on triple negative breast 
cancer (TNBC), which is a typical aggressive solid tumor with immunosuppressive TME and poor 
prognosis. Furthermore, we compared our nanoparticle delivery system with commercial available 
therapeutic modalities. Our study shown our delivery system provided an enhanced therapeutic 
strategy to remodel the immunosuppressive TME and further facilitate checkpoint blockade based 







CHAPTER 2: NANOCARRIER-MEDIATED IMMUNOGENIC CHEMOTHERAPY 
FOR TRIPLE NEGATIVE BREAST CANCER2 
1. Summary 
Triple negative breast cancer (TNBC) does not respond to checkpoint blockade 
immunotherapy as a result of immunosuppressive tumor microenvironment. To remodel the tumor 
microenvironment, we developed a liposome formulation to deliver a potential immunogenic cell 
death (ICD) inducing agent, 17-(allylamino)-17-demethoxygeldanamycin (17-AAG, or 
tanespimycin), in a tumor targeted manner to reverse the immunosuppressive microenvironment 
and facilitate the checkpoint blockade immunotherapy. The 17-AAG liposomes was prepared by 
thin film dispersion methods. The orthotopic 4T1 murine triple negative breast cancer model was 
studied. 17-AAG delivered by liposome remodeled the immunosuppressive microenvironment, 
significantly increased tumor infiltrating T cells, lowered the hypoxia level, decreased the 
suppressive lymphocytes such as tumor associated macrophages and myeloid derived suppressor 
cells in the tumor microenvironment. In addition, real-time PCR analysis revealed that chemokines 
and cytokines with immunosuppressive properties were notably reduced, which further facilitated 
the T cell mediated immunotherapy. Despite the fact that low dose 17-AAG liposomes 
demonstrated a limited therapeutic effect alone on 4T1 tumor, promising efficacy was observed 
when 17-AAG liposomes combined with checkpoint blockade immunotherapy. Taken together, 
 
2 This Chapter previously appeared as a research article in Journal of Controlled Release. The original citation is as 
follows: Liu, Y., et al., Nanocarrier-mediated immunogenic chemotherapy for triple negative breast cancer. J 
Control Release, 2020. 323: p. 431-441.  
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17-AAG liposomes could remodel the immunosuppressive microenvironment of triple negative 
breast cancer and facilitate the checkpoint blockade immunotherapy.  
2. Introduction 
Breast cancer is the second leading cause of cancer-related death in women, with an 
average risk of 12% to develop breast cancer in normal women life [168, 169]. Breast cancer has 
also the highest incidence rate and the second death rates among all types of cancer [169]. With 
the development of early detection and diagnosis technology and increased awareness, although 
death rate has already decreased since the past 30 years, breast cancer remains to be a main threat 
to women [168, 170, 171]. Prognosis and survival rate of breast cancer varies between different 
subtypes, and triple negative breast cancer (TNBC) is characterized as the most aggressive cancers 
with high metastatic rate and poor survival prognosis [168, 170] due to hormone receptors (PR, 
ER) or human epidermal growth factor receptor 2 (HER2) deletion which hinders early diagnosis 
tools and targeted therapy [172]. Few treatment options exist outside of chemotherapy for TNBC 
[173, 174].  
In recent years, the emergence of immune checkpoint blockade therapies redefined the 
cancer treatment [175-177]. Checkpoint blockade therapy had unprecedented success in halting 
the progress of advanced cancer such as melanoma, head and neck cancer etc.[177]. Immune 
checkpoint blockade therapy successfully blocks inhibitory signals for T cell activation to initiate 
effective anti-tumor responses [177]. Remarkable responses have been seen on deadly cancers 
such as lung cancer and colorectal cancers, while barely report of success has been reported on 
TNBC patients [178-180]. Previous study suggested that response to immunotherapy is depends 
on the high tumor immunogenicity, characterized by sufficient lymphocytes infiltration and high 
mutational load in the tumor [181]. TNBC, However, is a relatively “cold” tumor with minimal T 
cell infiltration and abundant suppressive immune cells [182, 183]. Therefore, to increase the T 
37 
 
cell infiltration and decrease the immunosuppressive cells in tumor microenvironment is the key 
to provoke strong immune response for TNBC patients [182]. 
High tumor immunogenicity can be achieved by generating immunogenic cell death (ICD) 
of the tumor cells [1, 184]. ICD is a form of cell death induced by chemotherapy, radiation therapy 
and photodynamic therapy [184]. ICD increases the tumor immunogenicity through activation of 
dendritic cells and specific T cells [1].  Two widely recognized biomarkers for ICD, calreticulin 
(CRT) and high mobility group box 1 (HMGB1), once exposed to the cell surface or release from 
nuclear to cytosol, would initiate signals to recruit and activate professional phagocytes [184]. 
Specific tumor antigens would be presented to T cells and promote strong antitumor immune 
response [185].  
Hypoxia (low oxygen level) is a common character in many types of cancers, especially 
desmoplastic cancers like TNBC [186]. In hypoxic condition, tumor cells activate several survival 
pathways to facilitate tumor progress and develop chemotherapy resistance [187]. Strong 
correlation between elevated level of HIF-1α and poor patient prognosis and increased drug 
resistance have been confirmed by numerous preclinical and clinical studies [186]. Hypoxia 
inducible factors activates genes encoding the tumor vascularization and growth, recruit stromal 
cells and remodel the extracellular matrix [186]. HIF1α also contributes to the immunosuppressive 
microenvironment by recruiting Treg cells and suppressing tumor infiltrating T cells. In addition, 
HIF1α promotes tumor growth by recruiting tumor associated macrophages (TAM) and myeloid 
derived suppressor cells (MDSC) [188]. Hypoxia also increases the expression of PD-L1 on 
macrophages, dendritic cells and tumor cells through a HIF1α dependent pathway, which suggests 




To address the poor immunogenicity and immunosuppressive microenvironment of TNBC, 
the ideal candidate should have the dual roles to remodel the tumor microenvironment and 
facilitate checkpoint blockade immunotherapy. Commonly recognized ICD inducing agents have 
played an important role in calcium-mediated activation of endoplasmic reticulum (ER) stress [1]. 
During rapid oncogenic transformation process in tumor, increased misfolded proteins 
accumulated in the ER and processed by chaperones like Hsp90 [190-192]. Inhibition of Hsp90 
activity further promotes protease activity, resulting in cell apoptosis and tumor antigen release 
[192]. Therefore, we proposed that 17-(allylamino)-17-demethoxygeldanamycin (17-AAG), as a 
potent Hsp90 inhibitor, is a promising ICD inducer. In addition, HIF1α is a Hsp90 client protein 
which can be downregulated by 17-AAG [193]. Other studies in our group also suggested the 
synergistic effect of ICD inducing agent with checkpoint blockade immunotherapy [149]. In this 
work, we identified 17-AAG as a potent ICD inducer and formulated 17-AAG in tumor-targeted 
liposome to specifically induce ICD within tumor microenvironment, remodel the 
immunosuppressive microenvironment and promote the anti-tumor response combining with 
checkpoint blockade  
3. Materials and Methods 
3.1. Materials 
17-AAG were purchased from Cayman Chemical (Ann Arbor, Michigan). 1,2-Dioleoyl-
sn-glycero-3-phosphocholine (DOPC) were purchased from Avanti Polar Lipids Inc (Alabaster, 
Alabama). 1,2-distearoyl-sn-glycero-3-phosphoethaolamine-N-[amino(polyethylene glycol)-2000 
(DSPE-PEG-2000), 3-(N-succinimidyloxyglutaryl)aminopropyl, polyethyleneglycol-carbamyl 
distearoylphosphatidyl-ethanolamine (DSPE-PEG-NHS) were purchased from Avanti Polar 
Lipids (Alabaster, AL). DSPE-PEG-aminoethyl anisamide (DSPE-PEG-AEAA) was synthesized 
following previous reported protocol [194].  
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3.2 Cell lines and animals 
 
Murine triple negative breast cancer cells 4T1 were obtained from UNC Tissue Culture 
Facility. 4T1 cells were cultivated with RPMI 1640 medium supplemented with 10% fetal bovine 
serum (V/V, Gibco) and 1% antibiotic-antimycotic (V/V, Gibco) at 37 C and 5% CO2 in a 
humified atmosphere following ATCC instructions. Human breast cancer cells MCF-7 were 
obtained from UNC Tissue Culture Facility. MCF-7 cells were cultivated with EMEM medium 
with 10% fetal bovine serum (V/V, Gibco) and 1% antibiotic-antimycotic (V/V, Gibco) at 37 C 
and 5% CO2 in a humified atmosphere following ATCC instructions. Six-week old female 
BALB/c mice were obtained from Jackson Laboratories. All animal handling procedures were 
approved by the University of North Carolina at Chapel Hill’s Institutional Animal care and Use 
Committee. 
3.3. Preparations and characterization of 17-AAG loaded AEAA-modified liposome 
DSPE-PEG-AEAA was prepared following previously reported methods [194]. 4-
Methoylbenzoyl chloride and 2-bromoethylamine hydrobromide were mixed for 5 h at room 
temperature before DSPE-PEG-NH2 was added and stirred at 65-70 C overnight in oil bath. The 
obtained reactant was purified by precipitation with diethyl ether, lyophilized and dissolved in 
chloroform. 17-AAG liposome was prepared by thin film dispersion method. Briefly, 17-AAG, 
DOPC, cholesterol, DSPE-PEG and DSPE-PEG-AEAA were dissolved in in chloroform/methanol 
(2/1, v/v) in a round bottle flask. Rotary evaporator was used to remove the organic solvent. Thin 
film was hydrated with PBS solution at 37 C for 1 h. The final concentration of 17-AAG liposome 





3.4. Characterization of 17-AAG liposome 
Size distribution of 17-AAG liposome was determined by dynamic light scattering (DLS) 
with Zeta nanosizer Z. The morphology was characterized by transmission electron microscopy 
(TEM). The sample was dried on a carbon-coated copper grid before measurement. Loading 
capacity was measured directly by the encapsulated 17-AAG. The sample was centrifuged with 
Amicon centrifuge tube (Millipore, USA) at a speed of 4000 rpm for 20 min. The supernatant was 
removed and the residue was dissolved in ethanol and the concentration was measured by HPLC.  
3.5. DC cell activation by antigen pulsing 
DC 2.4 mouse dendritic cell line were obtained from EMD Millipore. The culture medium 
was prepared with RPMI-1640 with 10% FBS, 1x L-Glutamine, 1xnon-essential amino acids, 1x 
HEPES buffer solution and 0.005X β-mercaptoethanol. 4T1 cell conditioned medium was 
obtained after 24 h incubation with 17-AAG or PBS and added to DC 2.4 cell incubation plate for 
another 24 h. The images for pulsed DC cells were acquired with microscope.  
3.6. Biodistribution study 
0.1% DiI were formulated in the bilayer of liposomes. DiI-labeled liposomes were 
intravenously injected to mice. The biodistribution of the DiI-labeled liposomes in major organs 
were visualized with the IVIS optical system 24 h after injection. The excitation wavelength was 
520 nm and the emission wavelength was 560 nm.  
3.7. Flow cytometry assay 
Fresh tumor tissues were obtained and prepared as single cell suspensions and the tumor 
infiltrating lymphocytes were quantified by flow cytometry. Briefly, fresh isolated tumors were 
incubated with collagenase and DNase for 1 h at 37 C to obtain singe cell suspension. The cells 
were treated with ACK buffer to lyse the red blood cells and dispersed in FACS buffer. Single cell 
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suspensions were stained with a cocktail of fluorescently labeled antibodies for 0.5 h. Then the 
cells were fixed with 4% PFA and analyzed with FCAS (BD LSR II). The analysis was performed 
with FlowJo software (TreeStar, Ashland, OR). Fluorescently labeled antibodies used for flow 
cytometry are listed in Table S1.  
3.8. Western blot assay 
Fresh tumors were harvested and homogenized in RIPA buffer. Total protein concentration 
of each sample was measured with bicinchoninic acid protein kit (BCA protein assay kit, Pierce). 
Quantified proteins were loaded on 4-12% sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE electrophoresis) (Invitrogen, CA) and transferred onto 
polyvinylidene difluoride membranes (Bio-Rad, CA). Membranes were blocked with 5% bovine 
serum albumin (BSA) for 1h before incubation with primary antibodies for 12 h at 4 C. 
Membranes were then incubated with horseradish peroxidase-coupled secondary antibodies and 
the signals were detected with the Pierce ECL Western Blot substrate (Thermo, Rockford, IL). 
ImageJ software was used to quantify the relative expression levels of protein.  
3.9. Quantitative real-time PCR assay 
Whole tumor RNA was obtained from freshly harvested tumor tissue via RNeasy 
microarray mini kit (Qiagen) and cDNA were obtained by reverse transcription via the iScriptTM 
cDNA synthesis kit (BIO-RAD) and amplified with Taqman gene expression master mix. Mouse 
specific primers were used and GAPDH were set as endogenous control. Reactions were 
completed with the 7500 Real-Time PCR system and the data were analyzed with the 7500 





3.10. Immunofluorescence staining and Masson Trichrome staining 
The freshly harvested tumor tissues were fixed in 4% PFA for 48 h and 5 µm cryostat 
sections were obtained and attached to the positive charged slides. Permeabilization was performed 
with PBS supplemented with 0.1% Triton X-100 before blocking with 2% BSA for 1 h. The slide 
samples were incubated with diluted fluorescently conjugated antibodies at 4 C for 12 h and nuclei 
were stained with prolong diamond antifade mountant with DAPI (ThermoFisher Scientific). The 
sections were examined under confocal microscopy (Zeiss, LSM 710) and quantified with ImageJ 
software. Five randomly selected fields were used for statistical analysis. The antibodies used for 
immunofluorescence staining are listed in Table S2. 
To detect the collagen in tumor tissues, paraffin-embedded tumor slides were stained with 
Masson Trichrome by UNC Tissue Procurement Core. Nikon Microscopy with 20× and 40× 
objectives were used to image the slides.  
3.11. TUNEL assay 
TUNEL Assay was carried out utilizing a DeadEnd Fluorometric TUNEL assay kit 
(Promega) following manufacturer’s instructions. The tumor frozen slides were prepared and 
fluorescently dye was used to stain the fragmented DNA of apoptotic cells. Slides were washed 
with PBS and covered with prolonged diamond antifade mountant with DAPI (ThermoFisher 
Scientific). Images were taken by confocal microscopy (Zeiss, LSM 710). 
3.12. Toxicity and safety evaluation 
Mouse body weight was measured every other day following the first treatment. At the 
endpoint of the animal study, mice were sacrificed, whole blood and serum were collected for 
blood chemistry analysis. Aspartate aminotransferase (AST), blood urea nitrogen (BUN), 
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creatinine (CRE) and alanine aminotransferase (ALT) were analyzed as indicators of renal and 
hepatic function. Whole blood was also analyzed to measure myelosuppression.  
To evaluate the organ specific toxicity, major organs including heart, liver, spleen, lung 
and kidney were fixed and examined by H&E staining by UNC histology facility.  
3.13. Statistical analysis 
Results were expressed as meanSD. For comparison within two groups, unpaired two-
tailed t test was used. For comparison among multiple groups, one-way analysis of variance 
(ANOVA) was used. GraphPad 6.0 was used for statistical analysis.  A p value less than 0.05 was 
considered to be significant.  
3.14. Tumor growth inhibition 
Female Balb/c mice, 6-8 weeks old, were inoculated with 1106 4T1 cells in the mammary 
fat pad when the tumor volume reaches 100 mm3.The mice were randomly separated into four 
groups as follows: untreated groups (PBS), 17-AAG liposome treated groups, anti-PD-L1 treated 
groups and combination treated groups (17-AAG liposome and anti-PD-L1 antibody). 17-AAG 
liposome were given intravenously every two days and anti-PDL1 antibody were given 
intraperitoneally every five days. The tumor volumes were measured by caliper every 3 days and 
calculated as V=0.5lengthwidthwidth, which the length represents the long axis and the width 
represents the short axis.  
3.15. CRT and HMGB1 staining 
To detect the surface ICD marker of CRT, 4T1 cells were incubated with 20 nM 17-AAG 
for 4 h at 30 C in a humidified atmosphere. After incubation, medium was replaced and cells were 
washed three times with PBS and fixed with 0.25% PFA for 10 min. Then the cells were washed 
three times with PBS and blocked with 1% BSA solution for 30 min. Cells were incubated with 
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diluted primary antibody for 12 h at 4 C and washed three times with PBS. Secondary antibody 
was added to cells and incubated for 1 h at room temperature. After washing with PBS for three 
times, cells were fixed with 4% PFA and mounted with Prolonged Diamond Antifade DAPI 
Mountant for confocal imaging. 
To detect the intracellular ICD marker of HMGB1, 4T1 cells were incubated with 20 nM 
17-AAG for 6 h at 37 C in a humidified atmosphere. Then the cells were washed three times with 
PBS and fixed with 4% PFA for 20 min and permeabilized with 0.1% Triton X-100 in PBS for 10 
min, blocked with 1% BSA for 30 min and incubated with primary antibody for 12 h at 4 C. 
Afterwards, cells were washed three times with PBS and incubated with secondary antibody for 1 
h at room temperature. Prolonged Diamond Antifade Mountant DAPI was mounted on cells before 
confocal imaging. Relevant primary antibodies, fluorescent secondary antibodies used for CRT 
and HMGB1 staining are listed in Table S3.  
4. Results and Discussions 
4.1 Poor immunogenic feature of 4T1 triple negative breast cancer 
Patients with TNBC failed to benefit from αPD-L1 treatment, which attributed to hypoxic 
immunosuppressive microenvironment and minimal T cell infiltration [195]. 4T1 is a highly 
tumorigenic, poorly immunogenic mammary carcinoma mimicking the stage IV of the TNBC 
[196]. We established the orthotopic 4T1 model and treated the mice with αPD-L1 on day 9,13 
and 17 (5 mg/kg). In accordance with clinical results, only slightly tumor inhibition was observed 
(Supplemental Figure 1.1A), suggesting the necessity of a combination strategy. Further 
immunostaining analysis and quantitation revealed the limited T cell infiltration in αPD-L1 treated 
mice, as well as the highly expressed HIF1α level. (Supplemental figure. 1.1B-D). HIF1α is over 
expressed in desmoplastic tumor, which characterized by abundant infiltration of tumor associated 
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fibroblast (TAF) [189, 197]. Therefore, the ideal candidate would be a bi-functional agent, which 
could favorably increase the T cell infiltration and ameliorate the hypoxia tumor 
microenvironment.  
4.2. Preparation and characterization of 17-AAG liposome 
HIF-1α, a key modulator of hypoxic tumor microenvironment, is a client protein of heat 
shock protein 90 (Hsp90). Hsp90 is a chaperone protein which overexpressed in tumor tissues, 
facilitating the proper maturation of the client protein to maintain the proliferation of the tumor 
cells. Previous study shown that the hypoxia level could be significantly downregulated with 
Hsp90 inhibitor. In addition, the inhibition of Hsp90 could induce ER stress, which is an obligatory 
condition for immunogenic cell death (ICD). 17-AAG, a first generation of Hsp90 inhibitor, were 
chosen as an ICD candidate. Here we tested 17-AAG, as an Hsp90 inhibitor, could be ICD inducer, 
consequently increase T cell infiltration in 4T1 tumor model. With two ICD markers, CRT and 
HMGB1 [184], we confirmed that 17-AAG could induce ICD in 4T1 cell line at very low dose (20 
nM) in a short time (3-6 h) (Figure 2.1B). The quantitation for the immunostaining of CRT and 
HMGB1 was analyzed by ImageJ software and significant ICD effect was observed (Figure 2.1B). 
An effective anti-tumor immune response is accompanied with activation of dendritic cells. The 
DC 2.4 cells were pulsed with the conditioned media which was prepared by incubating 4T1 cells 
with 20 nM 17-AAG for 24 h. After 24 h incubation, significant morphology changes of dendritic 
cell were observed, suggesting the activation of dendritic cell by active substance released from 
17-AAG treated 4T1 cells (Figure 2.1C). A similar ICD effect was also observed in human breast 
cancer cell line MCF-7 (Supplemental Figure 1.2 A-B). 
Clinical application of 17-AAG as the first Hsp90 inhibitor was hindered regardless of 
significant anti-tumor efficacy as a result of poor water solubility and limited bioavailability 
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(Figure 2.1A). Observations of hepatoxicity, renal failure and gastrointestinal toxicity have been 
reported both in preclinical and clinical studies [198, 199]. An efficient targeted nanoparticle 
platform is needed to improve drug solubilization, achieve the therapeutic effect and reduce the 
side effect [194].  
According to previous studies, the nanoparticle formulated drug shows an enhanced drug 
accumulation in tumor due to the enhanced permeability and retention (EPR) effect [200]. To 
facilitate future clinical usage, we formulated the liposome with DOPC and cholesterol, which are 
approved by FDA [201]. To reduce unfavorable side effect, tumor specific target AEAA 
(Supplemental Figure 1.2D) were conjugated on the surface of the liposome to target the sigma 
receptor, which is highly expressed in 4T1 breast cancer model (Supplemental Figure 1.2C) [202]. 
In our previous study, we have established a murine TNBC model with 4T1 cells, and 
demonstrated that nanoparticles conjugated with aminoethyl anisamide (AEAA) to facilitate a 
targeted delivery to 4T1 model [202].  
The 17-AAG was formulated by thin film dispersion methods, which is simple and can be 
easily scaled up (Supplemental figure 1.3). The 17-AAG liposome formulation was opalescent 
with a light pink color, which is shown in Figure 2.1D. The drug loading content was measured 
by HPLC. The measured encapsulation efficacy is 92%, with corresponding drug loading 
capability of 4.8%. Further physicochemical analysis revealed that the average particle size was 
around 85 nm (Figure 2.1D) and the zeta potential was -4 mV (Supplemental figure 1.4A), 
suggesting a uniform and nearly neutral liposome population. The morphology of 17-AAG 
liposome was confirmed by TEM as shown in Figure 2.1D. The 17-AAG liposome exhibited good 
stability profile for about 15 days under room temperature, showing a clinical translational 
potential of tumor targeted 17-AAG formulation (Figure 2.1E). To test the stability of the 17-AAG 
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liposomes in serum, we performed the drug release study and compared the release profile of 17-
AAG liposomes in the presence or absence of serum (Supplemental figure 1.4B). There is no 
significant difference in the release profile in media supplemented with or without serum, 
suggesting the presence of PEG on the surface of liposomes prevents 17-AAG liposomes from 
binding to the serum proteins (Supplemental figure 1.4A-B). In vitro dissolution studies were 
performed and compared with free drug and other formulation. Almost 100% of the drug released 
in the first 24 h from free 17-AAG solution in DMSO or in Cremophor/Ethanol. In contrast, 17-
AAG liposomes exhibited a slow release profile with about 10% loaded drug released in the first 
24 h. (Figure 2.1F). Further in vitro analysis suggested 17-AAG liposomes increased the anti-
tumor activities compared with free 17-AAG (Supplemental figure 1.4C-D). The in vitro anti-
tumor activities of free 17-AAG and 17-AAG liposomes were measured in 4T1 and MCF-7 cell 
lines (Supplemental figure 1.4C). Compared with free 17-AAG, 17-AAG liposomes exhibited 
increased cytotoxicity in tumor cell lines. The result indicated that anti-tumor activities could be 
achieved by 17-AAG liposomes at low concentration, i.e., decreased IC50 values (about 70nM), 
compared with free drug (Supplemental figure 1.4C). In contrast, the cytotoxicity of free 17-AAG 
and 17-AAG liposomes on normal cell line, Raw 264.7, was much lower. IC50 for both free and 
liposomal drug was about 0.5 µM, 9-fold higher than those for the two tumor cell lines 
(Supplemental figure 1.4D). Hence, both the 17-AAG and the 17-AAG liposomes are non-toxic 





Figure 2.1 Preparation and characterization of the targeted 17-AAG liposomes. 
(A) The chemical structure of 17-AAG. (B) The immunofluorescence staining and corresponding quantitative 
analysis of the 4T1 cells treated by 17-AAG and PBS. HMGB1, high mobility group protein B1; CRT, calreticulin. 
Positive ratios were quantified based on 5 randomly chosen fields per treatment. *** p<0.001. (C) DC 2.4 cells were 
pulsed with condition medium for 24 h from 17-AAG treated 4T1 cell. The scale bar represents 100 μm. (D) The 
particle size and TEM image of the 17-AAG liposomes. The average particle size of 17-AAG liposomes was 80 nm. 
The scale bar represents 100 μm. (E) The in vitro stability assay of 17-AAG liposomes. (F) The release profile of 




Figure 2.2 The in vivo characterization of the 17-AAG liposomes. 
17-AAG liposomes were given by i.v. injection into 4T1 bearing mice. (A) The IVIS image of DiI-labeled 17-AAG 
liposomes and PBS in 4T1 bearing mice. (B-C) The IVIS image and quantitative analysis of DiI-labeled 17-AAG 
liposomes biodistribution in separated organs and tumors. (D) The pharmacokinetics of 17-AAG liposomes in vivo 
analyzed with LC/MS. The half-life of the liposome was 9.0 h after i.v. injection. (E-F) In vivo immunofluorescence 
staining and quantitative analysis of 4T1 bearing mice tumor after PBS and different dose of 17-AAG liposomes 




The safety concern arisen with clinical application of 17-AAG as moderate side effect were 
observed in clinical trials [198]. In vitro analysis suggested 17-AAG liposomes increased the anti-
tumor activities compared with free 17-AAG. To further test the targeted effect of this delivery 
system, we formulated hydrophobic dye DiI in the bilayer of the liposomes and intravenously 
50 
 
injected into the mice. Twenty-four h post injection, the biodistribution of 17-AAG liposomes was 
investigated by tracking the DiI-labeled liposomes in 4T1-bearing mice (Figure. 2.2A). The mice 
were then sacrificed and the major organs including tumors were examined via the IVIS imaging, 
which is shown in Figure 2.2B. The organs were weighted and the ratio of fluorescence intensity 
to organ weight were calculated and plotted in Figure 2.2C. Significant liposome accumulation in 
the tumor were achieved, with secondary accumulation in liver, lung and spleen. We concluded 
that tumor specific targeted delivery with minimal off-target effect was achieved with our 
formulation.  
The pharmacokinetics profiles of 17-AAG liposomes were characterized by HPLC and 
plotted as Figure 2.2D, fitting a two-compartment distribution model, with a total area-under the 
curve (AUC) of 115 μg×h/mL and a half-life of 9.0 h. Notably, the half-life of formulated 17-AAG 
was significantly prolonged with AEAA-modified liposome, compared with unformulated 17-
AAG (Figure 2.2D) [198]. In consideration of the slow release profile of 17-AAG liposome 
(Figure 2.1F), most of the administered 17-AAG liposomes were able to accumulate and release 
inside the tumor microenvironment, which further lower the potential side effect on normal tissues. 
Both the in vitro and in vivo characterization shown that the AEAA-modified liposomes exhibited 
a tumor specific targeting profile with prolonged blood circulation time and minimal normal organ 
accumulation.  
To determine the proper in vivo dose to induce immunogenic cell death by 17-AAG, mice 
were inoculated with 1106 4T1 cells in the mammary fat pad and received different doses of 
treatment. On day 8, 10 and 12, mice were randomly distributed into 4 groups to receive different 
doses of 17-AAG liposomes. Mice were sacrificed at day 15 and fresh tumor tissue were obtained 
for ICD hallmark immunostaining (Figure 2.2E). Significant increase of CRT exposure and 
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HMGB1 release have been observed in the 5 mg/kg 17-AAG liposomes groups (Figure 2.2F). This 
optimized dose (5 mg/kg) was used for further animal studies.  
4.3. Synergistic effect of 17-AAG liposomes and αPD-L1 antibody in 4T1 breast carcinoma. 
Previous studies suggested that the tumor immunogenicity is a predictor of checkpoint 
blockade therapy response and the increased immunogenicity could help to fine-tune the 
immunotherapy outcomes [184, 203, 204]. Other studies in our group also suggested the 
synergistic effect of ICD inducing agent and checkpoint blockade immunotherapy [149]. To 
explore whether the tumor microenvironment modulation could further facilitate immunotherapy 
in triple negative breast cancer, we designed a combination experiment to test if low dose 17-AAG 
liposomes treated 4T1 carcinoma bearing mice could benefit from subsequent αPD-L1 
immunotherapy, the dose schedule was shown on Figure 2.3A. In agreement with previous study, 
we found that only minor tumor inhibition effect have been observed in 4T1 bearing mice treated 
alone with αPD-L1 [149]. In addition, no significant benefit has been seen in the low dose17-AAG 
liposomes alone treated group (Figure 2.3B).  
However, the tumor inhibition efficacy was favorably enhanced when 17-AAG liposomes 
were given prior to αPD-L1. The 4T1 tumor was primed with 5 mg/kg 17-AAG liposome on day 
6, 9 and 12 and the αPD-L1 (100 μg per mouse per dose) were given subsequently on day 9, 13 
and 17. Tumor mass measurement suggested significant synergistic effect in 17-AAG liposomes 
and αPD-L1 combination group (Figure 2.3B-D). Furthermore, as a highly metastatic TNBC 
model, 4T1 spontaneously metastasized to lung, pericardium and liver, which suggested the end 
stage of TNBC [205, 206]. In contrast to the PBS treatment, which obvious metastasis were seen 
in major organs such as lung, pericardium and liver (metastasis was indicated by black arrows), 
no obvious metastasis was observed in combination treatment groups (Figure 2.3E). To measure 
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the tumor cell apoptosis induced by different treatment, the TUNEL assay was performed to justify 
the treatment efficacy. In agreement with our tumor inhibition study, TUNEL assay in Figure 2.3F 
clearly shown that 17-AAG liposomes treatment increased the cell apoptosis rate by 6-fold 
compared with PBS treated groups (Figure 2.3G). Taken together, we concluded that 17-AAG 
liposomes and αPD-L1 treatment is a promising therapeutic strategy for triple negative breast 
cancer.  
 
Figure 2.3 Synergistic effect of 17-AAG liposomes and αPD-L1 in 4T1 triple negative breast cancer. 
(A) Dose schedule of 17-AAG liposomes and αPD-L1. 1x106 4T1 cells were inoculated on fat pad of female Balb/c 
mice. Mice were randomly distributed into 4 groups.  17-AAG liposomes were given by i.v. injection on day 6, 9, 12 
and αPD-L1 were given by i.p. injection on day 9, 13 and 17 after inoculation. (B) Tumor inhibition effect of 
various treatments. Combo, the combination treatment of 17-AAG liposomes and αPD-L1. (C) Representative tumor 
images of various treatments on day 23. (D) Quantitative analysis of tumor weight of different treatment groups. 
**p<0.005. (E) Representative images of lung, heart and liver tissue from PBS and combo treatment groups. Black 
arrows indicate metastasis. (F-G) TUNEL assay and corresponding quantitative analysis of tumor tissue from 
different treatment groups. Significant cell apoptosis was observed in 17-AAG liposomes treated groups. 
***p<0.001, ****p<0.0001. n=10. 
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4.4. Increase of immunogenicity of 4T1 breast carcinoma upon 17-AAG liposomes 
treatment. 
We examined the mechanism of 17-AAG liposomes to remodel the originally poorly 
immunogenic TME leading to facilitate the immunotherapy in 4T1 breast carcinoma. In the scope 
of cancer immunotherapy, three prerequisites were required to elicit a T cell mediated robust anti-
tumor response: (1) ICD primed DC activation to process and present tumor-specific antigens to 
T cell; (2) subsequent T cell activation and memory T cell response; (3) secretion of Th1 cytokines, 
especially those that act as T cell chemoattractants, such as C-X-C motif chemokine ligand 9 
(CXCL9) and C-X-C motif chemokine ligand (CXCL10), to increase infiltrating T cells within the 
poorly immunogenic TME. In concordance with our in vitro dendritic cell activation experiment 
(Figure 2.1C), in vivo experiment showed that the activated dendritic cell population was 
successfully increased upon 17-AAG alone and combo treatment (Figure 2.4A). Next, we 
examined if the activated dendritic cells would be able to further activate T cell and elicit a robust 
anti-tumor response. In the immunofluorescence staining assay we found a significant 10-fold 
increase in tumor infiltrating T cells in 4T1 breast carcinoma treated with 17-AAG liposomes 
(Figure 2.4B). In addition, flow cytometry analysis also revealed the significant changes both in 
CD8+ T cells and CD4+ T cells in 17-AAG liposomes treated tumor compared with untreated ones 
(Figure 2.4C). With flow cytometry analysis, we found that the memory CD8+T cells 
(CD62L+CD44+CD8+subpopulations) within TME were clearly elevated upon 17-AAG treatment, 
with nearly 7% memory CD8+ T cells compared with only 1% in the PBS treated group, suggesting 
a long term and robust anti-tumor response in 4T1 model (Figure 2.4E-F). In addition, two 
important chemoattractants for T cells, CXCL9 and CXCL10, were also found to be obviously 
increased by real-time PCR analysis (Figure 2.4D). To verify our hypothesis that the tumor 
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inhibition effect was caused ICD and was T cell dependent, we depleted the CD8+ T cells and 
CD4+ T cells separately with corresponding antibodies, and the tumor inhibition effect was 
compromised as expected (Figure 2.4G). Notably, 17-AAG liposomes successfully remodeled the 
poorly immunogenic TME, showing promising anti-tumor effect in the combination therapy with 
αPD-L1.  
Unfortunately, our tumor inhibition study only partially demonstrated the expected anti-
tumor effect for the following possible reasons. (1) The measured tumor volume failed to represent 
the true tumor volume. Clinical observations reported the presence necrosis zone in mature 
invasive breast cancer, which is also confirmed by our mouse study (Figure 2.4C). Our tumor 
volume measurement counted the total necrosis and alive tissue, whereas absolutely live tumor 
cells cannot be accurately estimated. (2) Our flow cytometry suggested that 4T1 TME were highly 
infiltrated with different immune cells, like MDSC and TAM. Tumor cell only accounts for a small 
fraction of total population. Overall, we concluded that 17-AAG treatment could significantly 
increase immunogenicity in 4T1 cancer model and elicit a robust anti-tumor effect when combined 






Figure 2.4 17-AAG liposomes treatment increased the immunogenicity of 4T1 triple negative breast cancer. 
(B) The immunofluorescence staining and corresponding quantitative analysis of 4T1 tumors using DAPI (blue) and 
anti-CD3 (red). Scale bar represents 50 μm. (C) CD8+T cells, CD4+T cells were measured by flow cytometry upon 
sacrifice on day 23. Quantitative analysis was performed with GraphPad 6.0. *p<0.05, **p<0.01, ***p<0.001. (D) 
Th1 cytokines which acted as T cell chemoattractants, were elevated in 17-AAG liposomes alone treatment and 
combination treatment. CXCL9, C-X-C motif chemokine ligand 9; CXCL10, C-X-C motif chemokine ligand 10. (E-
F) Flow cytometry and corresponding quantitative analysis of memory CD8+ T cells within the tumor. (G) T cell 




4.5. 17-AAG liposomes remodeled the tumor microenvironment as a potent HIF1α 
inhibitor. 
Hsp90 is a major molecular chaperone which plays a vital role in its client folding and 
functions within the cells [207, 208]. Many Hsp90 client proteins facilitate the tumor growth, 
promote tissue remodeling and metastasis [191]. An important Hsp90 client protein is HIF1α, 
which actively involved in the ΤΜΕ remodeling process [193, 209]. In addition, HIF1α is over 
expressed in desmoplastic tumor, which characterized by abundant infiltration of tumor associated 
fibroblast (TAF) [189, 197]. HIF1α promote the formation of extracellular matrix, enhance tumor 
suppression microenvironment by recruiting TAM and MDSCs, facilitate secreting 
immunosuppressive cytokines and chemokines such as PDGF-C, CCL2, FGF-2 and TGF-β which 
mediate the transformation to basal-like breast cancers [186, 197, 210, 211]. Clinical studies 
documented the elevated hypoxia level in TNBC, which is quantitated by immunohistochemistry 
(IHC) expression of hypoxia-inducible factor 1-alpha (HIF1α) [186, 212]. Further statistical 
analysis identified the significant correlation between elevated expression of HIF1α and poor 
prognosis of TNBC patients [212-214]. Hypoxia microenvironment further promotes the collagen 
synthesis and accumulation, forming a desmoplastic tumor, increasing drug resistance and 
compromising therapeutic efficacy [209]. HIF1α is highly expressed in 4T1 tumor cells 
(Supplemental figure 2.1C-D) and is a client protein of Hsp90 [193]. Therefore, the HIF1α level 
could be efficiently downregulated by 17-AAG treatment [193]. In our study, the PBS treated 
group and antibody treated groups showed highly expressed HIF1α (Supplemental figure 2.1C-D), 
which was significant decreased in 17-AAG liposomes treated group, as revealed by 
immunofluorescence staining in Figure 2.5A. We concluded that the desmoplastic 4T1 
microenvironment can be remodeled by HIF1α inhibition by 17-AAG liposomes. The collagen 
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content of the tumor in different treatment groups was characterized by Masson Trichrome staining. 
Significant decrease in collagen content was found in 17-AAG liposomes treated groups, 
compared with untreated group and αPD-L1 alone treated group (Figure 2.5A). A similar result 
was obtained from quantitation of tumor associated fibroblast, using α-SMA as biomarker. This 
strategy is particularly beneficial for desmoplastic tumors, which are notorious for enriched tumor 
associated fibroblast (TAF) [215]. TAF forms a solid barrier around tumor nest, compromising 
drug delivery efficacy. It is also shown that common chemotherapy drugs, once been taken up by 
TAF, would release Wnt16 to promote tumor proliferation and metastasis [216]. In our study, 
however, the drug delivery hurdle can be readily removed by 17-AAG liposomes, remodeling the 
immunosuppressive TME and facilitate the T cell infiltration into the TME.  
Meanwhile, the flow cytometry analysis results also suggested that the immunosuppressive 
microenvironment were successfully remodeled by 17-AAG liposomes treatment. 
Immunosuppressive microenvironment is characterized by key components such as myeloid cells 
and Th2 anti-inflammatory cytokines [217]. Major myeloid infiltrating cells, including TAM and 
MDSC, were significantly decreased in the 17-AAG liposomes treated groups (Figure 2.5C). Real-
time PCR analysis of the TME also suggested that key T helper 2 (Th2) cytokines, such as platelet 
derived growth factor C (PDGF-C) [218], basic fibroblast growth factor (FGF-2) [219], C-C motif 
chemokine ligand 2 (CCL2) [220], transforming growth factor beta (TGF-β) [221] which act as 
anti-inflammatory cytokines , were also significantly reduced with 17-AAG liposomes treatment 







Figure 2.5 TME modulation upon 17-AAG liposomes treatment. 
(A) Immunostaining of HIF1α and α-smooth muscle actin (A-SMA). Five fields were randomly chosen for imaging 
and quantitative analysis. (B) Relative mRNA expression in tumor microenvironment upon different treatments. The 
Th2 cytokines were decreased after 17-AAG liposomes and αPD-L1 treatment. PDGF-C, platelet derived growth 
factor C; FGF-2, basic fibroblast growth factor; CCL2, C-C motif chemokine ligand 2; TGF-β, transforming growth 
factor beta. (C) TAM and MDSC were measured by flow cytometry upon sacrifice on day 23. Quantitative analysis 









4.6. Toxicity and safety evaluation of different treatment groups. 
Safety and toxicity of therapy is one important aspect for novel therapy evaluations. Major 
organs (heart, liver, spleen, lung and kidney) from different treatment groups were obtained and 
stained with H&E. No morphological differences were observed between different treatment 
groups. In accordance with our observations, we found multiple lung metastasis in the PBS treated 
and anti-PD-L1 antibody alone treated groups, as indicated by black arrows in Figure 2.6A. In 
contrast, no liver or lung metastasis were found in 17-AAG liposomes alone and combination 
treatment groups. We obtained whole blood and blood serum from different treated groups on day 
23 to evaluate potential toxicity effect. No significant changes were found in serum ALT, AST, 
BUN and CREAT levels among different groups, indicating no severe hepatic or renal malfunction 
caused by different treatment (Figure 2.6B). Whole blood testing also revealed that no severe 
toxicity was observed (Table S1). As another component in toxicity studies, no significant body 
weight loss was found through the treatment schedule (Figure 2.6C). Together, those analysis 
indicate no obvious toxicity were found among different treatment groups, which suggest a 






Figure 2.6 Toxicity and safety evaluation of different treatment groups. 
(A) HE staining of different organs upon treatment. (B) The blood serum test of different treatment groups. (C) The 
body weight of different mice through the treatment schedule. Black arrows indicate metastasis. 
 
5. Conclusion 
In summary, we successfully identified that 17-AAG, as a hsp90 inhibitor, could induce 
immunogenic cell death and remodel the immunosuppressive tumor microenvironment in 4T1 
triple negative breast cancer. The animal experiment justified that 17-AAG liposomes could 
increase the T cell infiltration and facilitate the T cell mediated immunotherapy. The combination 
of 17-AAG and checkpoint blockade provide a novel strategy to increase the effectiveness of 













CHAPTER 3: LOCALLY TRAPPING C-C MOTIF CHEMOKINE LIGAND 2 
REMODELS THE IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT AND 
INHIBITS TUMOR PROGRESSION IN TRIPLE NEGATIVE BREAST CANCER 
1. Summary 
Adipocytes are the primary cellular component within the triple-negative breast cancer 
(TNBC) tumor microenvironment (TME). Recently, increasing evidence suggested the tumor-
associated adipocytes (TAA) can aggravate tumor progression, exacerbate immunosuppressive 
TME and compromise therapeutic effect. In this study, we first investigated the biological effect 
of TAA within breast cancer TME and identified C-C Motif Chemokine Ligand 2 (CCL2) as the 
key mediator which mainly secreted by TAA into the extracellular environment. CCL2 then act as 
the recruiter to recruit immune cells such as monocytes and macrophages which further 
differentiated into immunosuppressive myeloid-derived suppressor cells (MDSCs) and M2 
macrophages, respectively. We designed a protein trap which binds with CCL2 with high affinity. 
The plasmid DNA encoding the trap was specifically delivered to the TME by using targeted lipid-
protamine-DNA nanoparticles to locally express and trap CCL2 and ameliorated the 
immunosuppressive TME. Moreover, compared with commercially available CCL2 antibody, our 
strategy showed an enhanced therapeutic efficacy and significant tumor growth inhibition. 
Furthermore, the pCCL2 trap treatment successfully remodeled the immunosuppressive TME, 
increased T cell infiltration and decreased immunosuppressive M2 macrophage and MDSC 
population. We further demonstrated that pCCL2 trap could facilitate the pPD-L1 based 
checkpoint blockade immunotherapy, delivering a cure for TNBC with enhanced therapeutic effect 




Triple-negative breast cancer (TNBC) is one of the leading killers in women with high 
metastasis rate and poor prognosis. Few clinical benefits have been observed in TNBC patients 
receiving chemotherapy and radiotherapy [222]. In recent years, the development of checkpoint 
blockade-based immunotherapy (CTLA4, PD-1 or PD-L1 inhibitor) has greatly reshaped the 
landscape of cancer therapy. However, less than 20% response rate was achieved in TNBC patients 
owing to the immunosuppressive tumor microenvironment (TME) [222, 223]. Therefore, the 
development of effective remedies to reverse the immunosuppressive TME is crucial for TNBC 
treatment.  
TME is a heterogeneous and dynamic cellular milieu consists of a variety of resident and 
infiltrating cells [224]. Accumulated evidences have revealed the important role of TME in tumor 
initiation, progression, metastasis, therapeutic response and resistance [224]. Breast cancer is noted 
to have abundant and specific resident adipocytes within TME that differ considerably from other 
solid tumors [225]. Such distinctive cellular components difference in TME might help to better 
understand the mechanism that dictate the immunosuppressive TME formation of breast cancer.  
Adipocyte has long been considered as fuel tank to store energy in forms of lipid and 
triglycerides [226]. However, recent findings unraveled the diverse aspects of adipocyte and 
adipocyte derived factors [225, 227]. Clinical observations suggested that adipocytes which reside 
in close proximity with cancer cells exhibited tumor-associated functions and phenotypes, such as 
decreased size, overexpression of collage VI and chemokines [227]. Those specialized type of 
adipocyte is termed “tumor associated adipocyte (TAA)”. TAA may secret factors that will 
promote the immunosuppressive TME [227]. Furthermore, TAA may trans-differentiate into 
fibroblasts which enhance the desmoplasia of the tumor [227], further promoting the suppressive 
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immune microenvironment. An in-depth understanding of the biology of TAA might provide new 
opportunities to modify the immunosuppressive TME in TNBC and facilitate the development of 
promising therapies.  
C-C Motif Chemokine Ligand 2 (CCL2), which also referred to as monocyte 
chemoattractant protein 1 (MCP-1), is a potent inducible chemokine to recruit immune cells, 
particularly monocytes, to infiltrate into the inflammatory tissue region [228]. The plasticity nature 
of monocytes enables their phenotype transition and function changes in response to TME factors. 
Following infiltration into TME, monocytes are quickly polarized and differentiated into 
macrophages and myeloid-derived suppressor cells (MDSCs) accompanied with functional and 
phenotypical changes [229, 230]. It is widely documented that tumor-associated macrophages 
constitutes two major subtypes, M1 and M2 macrophages [231]. M1 and M2 macrophages are 
identified based on surface marker and secreted cytokines/chemokines, differ considerably in 
terms of phenotypes and functions [231]. M1 macrophage have a pro-inflammatory phenotype 
which actively produce high levels of pro-inflammatory cytokines/chemokines and promote Th1 
responses. On the contrary, M2 macrophage is featured by an anti-inflammatory phenotype which 
actively secret high amount immunosuppressive cytokines such as IL-10 and TGF-β. In addition, 
M2 macrophages repurpose arginase metabolic pathways to further promote tumor progression 
[231]. Clinical observations suggested that increased M2 macrophage density in the tumor is 
closely correlated with poor prognosis whereas increased M1 macrophage proportion usually 
signifies a favorable clinical outcome [232]. Moreover, further detailed gene expression profiles 
identified CCL2’s role as a potent driving factor for M2 polarization and Th2 response. Elevated 
CCL2 level positively correlates with enhanced M2 macrophage and MDSC population, inhibited 
T cell infiltration and other immunosuppressive factors that compromise the cancer 
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immunotherapy [230]. In this regard, blockade of CCL2 could be a feasible strategy to reverse the 
immunosuppressive TME and thereby facilitate checkpoint blockade immunotherapy. 
There are usually two common strategies for target-protein based therapy to block specific 
signaling axis: the small molecule inhibitors and the monoclonal antibodies (mAbs). Bindarit® is 
a small molecule inhibitor which exhibits broad inhibition of CCL2, CCL7 and CCL8. Previous 
study revealed only moderate inhibitory ability of Bindarit® over LPS induced production of CCL2 
in human monocyte with IC50 over 170 µM [233]. To address the clinical need of a selective 
inhibitor with enhanced potency and efficacy, CCL2-netralizing mAb was developed. Preclinical 
and clinical investigations confirmed the apparent efficacy of a systemic CCL2 mAb in breast 
cancers with moderate tumor inhibition effect and decrease in M2 macrophages and MDSCs in 
TME [234]. However, discontinuation of CCL2 mAb dosing triggered a rebound effect in CCL2 
expression, resulting in significant increase of M2 macrophage and MDSC infiltration and 
accelerated metastasis [234]. Further mechanism analysis revealed that the immediate cessation of 
systemic CCL2 mAb resulted in increased migration and infiltration of monocytes into the primary 
tumor and lung metastasis [235]. Therefore, a local and transient CCL2 blockade may be an 
effective strategy to modify the immunosuppressive TME. 
Recent advances in nanotechnology have opened up opportunities for the development of 
a local and transient in vivo mAb-like blockade with non-viral gene delivery platform [224]. 
Nanoparticles (NP) preferentially accumulate within the tumor via the enhanced permeability and 
retention (EPR) effect that depends on the leaky nature of abnormal vessels in solid tumors [224]. 
To further optimize the target efficacy, targeting ligands are often conjugated to NPs to facilitate 
specific uptake of NPs by cancer cells [236].  Non-viral synthetic plasmid DNA that encoded mAb, 
or mAb-like protein, gene was encapsulated and delivered into tumor TME in a targeted manner. 
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This approach turns the tumor into a biological factory to produce corresponding mAbs, or the 
likes, followed by extracellular secretion into the TME [237]. In this work, we first rationally 
designed a fusion protein, called “trap”, that contains a CCL2 binding domain. We then 
constructed and delivered a plasmid encoding CCL2 trap (pCCL2 trap) by using a tumor targeted 
lipid-protamine-pDNA (LPD) NP to the TME. We hypothesized that locally expressed trap will 
efficiently decrease concentration of CCL2, leading to TME remodeling. LPD NPs surface was 
grafted with polyethylene glycol and functionalized with the targeting ligand aminoethyl 
anisamide (AEAA) to reduce organ accumulation and improve delivery efficacy. AEAA is a high 
affinity ligand (Kd = 9 nM) for the sigma-1 receptor over-expressed in both tumor cells and the 
tumor associated fibroblasts [215]. We demonstrated with a murine orthotopic model of TNBC 
that pCCL2 trap delivered by LPD NPs preferentially accumulated within the TME, leading to a 
decrease in CCL2 level. In addition, compared with CCL2 mAb, our strategy modified the 
immunosuppressive TME without any rebound effect, reprogrammed TAAs into normal 
adipocytes, increased tumor inhibition efficacy and reduced lung metastasis. Furthermore, in 
combination of pPD-L1 trap-based checkpoint blockade immunotherapy, we observed a 




Scheme 1. Schematic illustration of the mechanism of pCCL2 trap for the treatment of TNBC in murine 
model of TNBC. A. Primary mammary breast tumor immunosuppressive TME constitutes of surrounding tumor 
associated adipocyte (TAA) and infiltrated immunocytes. B. pCCL2 trap successfully remodels the 
immunosuppressive TME of TNBC in the tumor model. 
 
3. Materials and Methods 
3.1. Materials 
1,2-dioleoyl-3-trimethylammonium propane chloride salt (DOTAP), 1,2-distearoyl-sn-
glycero-3-phosphoethaolamine-N-[amino(polyethylene glycol)-2000 (DSPE-PEG-2000), 3-(N-
succinimidyloxyglutaryl)aminopropyl, polyethyleneglycol-carbamyl distearoylphosphatidyl-
ethanolamine (DSPE-PEG-NHS) were purchased from Avanti Polar Lipids (Alabaster, AL). 





3.2. Synthesis of DSPE-PEG and DSPE-PEG-AEAA 
DSPE-PEG-AEAA was synthesized following previously reported methods (ref). Briefly, 
4-Methoylbenzoyl chloride and 2-bromoethylamine hydrobromide were mixed for 6 h at room 
temperature. Then the DSPE-PEG-NH2 was added into the mixture and stirred at 65-70 C 
overnight in oil bath. The obtained product was further precipitated and purified with diethyl ether, 
lyophilized and dissolved in DI water.  
3.3 Preparation and Characterization of LPD NPs 
LPD NPs were constructed via a sequential self-assembly process. Briefly, DOTAP and 
cholesterol were dissolved in chloroform in a round bottle flask. Rotary evaporator was used to 
remove the organic and prepare the lipid thin film. Lipid thin film was hydrated with deionized 
water and underwent extrusion to obtain 100 nm unilamellar blank liposomes. To formulate LPD 
NPs, 100 μL of 0.5 mg/mL protamine with 100 µL of 0.5 mg/mL pDNA encoding for 
GFP/CCL2/PD-L1 were first mixed to form a pDNA: protamine complex core. Then the 
previously prepared DOTAP: Cholesterol blank liposomes were added and mixed with pDNA: 
protamine complex core. Finally, DSPE-PEG and DSPE-PEG-AEAA were added in a post-
insertion manner. Size distribution and ζ potential of LPD NPs was determined by Malvern 
ZetaSize Nano Series. (Westborough, MA).  
3.4 Biodistribution of LPD NPs  
LPD NPs were labeled with DiI by incorporation of 0.1% lipophilic dye Dil into the blank 
DOTAP: cholesterol liposomes. Twenty-four hours post intravenous injection of DiI-labeled LPD 
NPs, mice were sacrificed and the biodistribution of DiI-labeled liposomes were visualized with 
the IVIS Kinetics Optical System (PerkinElmer, CA). Excitation wavelength of 520 nm and 
emission wavelength of 560 nm were used for IVIS imaging.  
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3.5. Cell Lines 
Murine triple negative breast cancer cells 4T1 were obtained from UNC Tissue Culture 
Facility. Following ATCC instructions, 4T1 cells were cultured with RPMI 1640 medium 
supplemented with 10% fetal bovine serum (V/V, Gibco) and 1% antibiotic-antimycotic (V/V, 
Gibco) in a humified atmosphere at 37 C and 5% CO2 conditions.  
3.6. Orthotopic Animal Mouse Cancer Model 
Six-week old female BALB/c mice were purchased from Jackson Laboratories and 
maintained under germ-free conditions. Orthotopic 4T1 model was established by orthotopically 
injection of 1×106 4T1 cells in 50 μL PBS into the mammary fat pad of female BALB/c mice. 
Subcutaneous 4T1 model was established by subcutaneous injection of 1×106 4T1 cells in 100 μL 
PBS into the right flank of female BALB/c mice. All animal procedures were approved by the 
Institutional Animal Care and Use Committee in University of North Carolina at Chapel Hill.  
3.7. Tumor Growth Inhibition Study 
The 4T1 tumor bearing mice were randomly distributed into different treatment groups 
when the tumor volume reaches 100mm3. Mice were treated with different modalities according 
to the treatment schedule. Tumor progression was recorded by caliper, and the tumor volume 
was calculated as V=0.5× length ×width ×width, where the length represents the long axis and 
the width represents the short axis.  
3.8. Flow Cytometry Assay 
Fresh tissues were obtained and prepared as single cell suspension. Tumor infiltrating 
lymphocytes were characterized and quantified by flow cytometry assay. In brief, fresh isolated 
tumors were first incubated with collagenase and DNase for 1h at 37 C to obtain single cell 
suspensions. Then the prepared single cell suspensions were stained with a cocktail of 
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fluorescently labeled antibodies for surface marker expression analysis. After 0.5 h staining, cells 
were fixed with 4% PFA solution and analyzed with FACS (BD LSR II). The analysis was 
conducted with FlowJo software (TreeStar, Ashland, OR). Fluorescently labeled antibodies used 
for flow cytometry are listed in Table S1.  
3.9. Immunofluorescence Staining 
Fresh tumor tissues were first resected and rinsed in PBS upon mice sacrifice and fixed 
with 4% PFA solution at 4 C for 48 h. Tissues were then dehydrated with 15% and 30% sucrose 
solution. Dehydrated tissues were embedded into O.C.T solution for the preparation of frozen 
section. Obtained cryostat sections were permeabilized and blocked with 5% goat serum for 1 h at 
room temperature. Then the sections were incubated with fluorescently conjugated antibodies for 
12 h at 4 C and mounted with Prolong Diamond Antifade Mountant with DAPI. IF images were 
taken on a confocal microscope (Zeiss LSM 710) and quantified with Image J. Five randomly 
chosen fields were used for statistical analysis. Antibodies used for immunofluorescence staining 
are listed in Appendix II.  
3.10. TUNEL Assay 
TUNEL assay were conducted using a DeadEnd Fluorometric TUNEL System (Promega, 
Madison, WI) following the manufacturer’s protocol. Tumor frozen section slides were prepared 
and the fragmented DNA of apoptotic cells were stained with fluorescent dye. Cell nuclei that were 
stained to be fluorescent green were defined as TUNEL-positive nuclei. Slides were further 
mounted with prolonged diamond antifade mountant DAPI (ThermoFisher Scientific) and 
examined under Confocal microscopy (Zeiss, LSM 710). Five microscopic fields were randomly 




3.11. Quantitative Real-Time PCR Assay 
RNeasy Microarray Tissue Mini Kit (Qiagen) were used to extract the total RNA from 
fresh tissues. cDNA was obtained by reverse transcription using the iScript cDNA Synthesis Kit 
(BIO-RAD) and amplified with Taqman gene expression master mix. Mouse specific primers were 
used and GAPDH was used as the endogenous control. Reactions and corresponding data analysis 
were completed with the 7500 Real-Time PCR system. Primers used in Real-Time PCR assay are 
listed in Applendix III.  
3.12. Safety Evaluation 
Mouse body weight were measured every other day following the first dose treatment. At 
the experiment endpoint, mice were sacrificed, whole blood, serum and major organs were 
collected for safety evaluation. Aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), blood urea nitrogen (BUN) and creatinine (CRE) levels in the serum were analyzed as 
biomarkers for renal and hepatic function. Red blood cells (RBC), white blood cells (WBC), 
platelets (PLT), hemoglobin (HGB) and hematocrits (HCT) in whole blood were measured to 
quantify myelosuppression.  
To evaluate the toxicity in major organs, heart, liver, spleen, lung and kidney from different 
treatment groups were harvested, fixed, stained with hematoxylin and eosin (H&E) and examined 
under microscope.  
3.13. Statistical Analysis 
Results are presented as mean ± SD unless otherwise specified. GraphPad 6.0 was used for 
statistical analysis. For comparison between two groups, student’s t test was used. For comparison 
within three or more groups, one-way analysis of variance (ANOVA) was used. Kaplan-Meier 
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estimator was used to analysis the survival studies. A p value less than 0.05 was considered to be 
significant. *, **, *** and **** denotes p<0.05, 0.01, 0.001, and 0.0001, respectively.  
4. Results and Discussion 
4.1． Tumor-associated adipocyte facilitate tumor progression and exacerbate 
immunosuppressive TME via secreting CCL2  
Adipocyte is one of the main resident cells that constitute the TME of TNBC [225].  
Previous studies suggested the interaction between adipocyte and cancer cell, while the clear role 
of tumor associated-adipocyte (TAA) remains undefined [227]. To better understand the 
interaction between mature adipocyte and TNBC cell, mature adipocytes were first differentiated 
from 3T3-L1 preadipocytes and then were cultivated in a transwell system in the presence or 
absence of 4T1 murine TNBC cells (Figure 3.1A). Significant morphological changes were 
observed in adipocytes cocultured with 4T1, which exhibited a significant decrease in lipid 
droplets size and contents (Figure 3.1B). In addition, further RT-PCR analysis revealed altered 
gene expression in 4T1 cocultured-adipocytes. The fatty acid binding protein 4 (FABP4), a highly 
exclusively expressed hallmark in mature adipocytes [227], was significantly downregulated by 2-
3-fold in 4T1 cocultured-adipocytes. In contrast, cytokine CCL2, a potent chemokine to recruit 
monocytes, was significantly upregulated (Figure 3.1C). 
Enlighted by the in vitro observations, we established in vivo 4T1 tumor models in the 
presence or absence of adipocytes on BALB/c mice, aiming to investigate the role of TAA in 4T1 
murine TNBC model. Same amount of 4T1 cells were inoculated on mammary fat pad or 
subcutaneously to establish orthotopic 4T1 model or subcutaneous 4T1 model, respectively 
(Figure 3.1D). The only significant difference between the two models is the presence or absence 
of resident adipocytes in tumor environment. A significant aggressive tumor progression was 
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observed in orthotopic 4T1 model compared with subcutaneous 4T1 model (Figure 3.1E-G). In 
addition, consistent with previous in vitro experiments, more detailed gene expression analysis by 
RT-PCR revealed that CCL2 mRNA was highly upregulated in orthotopic 4T1 model, whereas no 
significant differences in the mRNA expression levels of other tumor progression associated 
chemokines and cytokines between orthotopic and subcutaneous 4T1 models were found (Figure 
3.1H).  Moreover, orthotopic model revealed an immunosuppressive TME which was 
characterized by abundant infiltration of M2 macrophages, which were probably differentiated 
from the recruited monocytes via CCL2. Furthermore, activated T cells infiltration was 
considerably decreased, profiling an immunosuppressive TME in the orthotopic 4T1 model 
(Figure 3.1I).  
We next examined the clinical database to further verify our hypothesis. Among all organs 
and tissues, adipose tissue is the main source of CCL2 in human. Analysis of clinical specimens 
also revealed the prevalence of CCL2 expression in breast cancer patients and high expression 
CCL2 is positively correlated with shorter survival and poor prognosis in breast cancer patients 
(Supplemental figure 3.1). Taken together, these data supported our hypothesis that TAA actively 
participated in TNBC progression, exacerbate immunosuppressive TME by secreting excessive 
CCL2. Therefore, blockade of CCL2 holds great promise to remodel the immunosuppressive TME 







Figure 3.1 Tumor-associated adipocytes facilitate tumor progression and exacerbate immunosuppressive 
TME via secreting CCL2. 
 (A) Cultivation of mature adipocytes in the presence or absence of 4T1 cells. Mature adipocytes were first 
differentiated from preadipocyte 3T3-L1 and cocultured with or without 4T1 cells in a transwell system. (B) A 
significant decrease in lipid droplets size and contents was observed in mature adipocytes cocultured with 4T1 cells. 
Lipid droplets were stained by Oil-Red-O. (C) RT-PCR analysis of cultivated mature adipocytes in the presence or 
absence of 4T1 cells. CCL2: C-C Motif Chemokine Ligand 2; FABP4: fatty acid binding protein 4. (D) Establishment 
of subcutaneous or orthotopic 4T1 mouse model. On day 0, 1×106 4T1 cells were inoculated orthotopically on 
mammary fat pad or subcutaneously in six-week old female BALB/c mice. (E) Representative picture of tumor burden 
from orthotopic and subcutaneous 4T1 mouse model on day 21. (F)  Tumor progression curve of orthotopic and 
subcutaneous 4T1 mouse models. **p<0.01. (G) Quantitative analysis of tumor weight of orthotopic and subcutaneous 
4T1 mouse model on day 21. **p<0.01. (H) Relative mRNA expression of various chemokines and cytokines in 
tumors from orthotopic and subcutaneous 4T1 mouse models. **p<0.01; ns, not significant.  (I) CD3+ T cell and M2 
macrophage population in the tumors from orthotopic and subcutaneous 4T1 mouse models. Cells were identified by 
using flow cytometry. **p<0.01, ***p<0.001.  
 
4.2. Preparation and characterization of in situ CCL2 blockade depot 
Our plan was to first design a relatively high affinity binding protein, i.e. a trap, to be 
expressed in TME to capture CCL2. We screened a VH domain library displayed on the yeast cell 
surface  [238]and obtained a CCL2 specific trap protein.  The trap was engineered with C-terminal 
C-myc and His x6 tags to facilitate purification and signal detection. The theoretical molecular 
weight was 15.8 kDa. The recombinant trap protein was expressed in Expi 293 cells and purified 
by using Ni-NTA affinity chromatography. The binding affinity to murine CCL2 was measured 
by using trap protein immobilized via the His tag on a Biacore facility. The estimated Kd was ~ 
229 nM. No detectable binding with CCL8 and only a weak binding with CCL7 was detected. The 
trap also did not bind with all other CCL ligands. The CCL2 trap gene was codon optimized for 
expression in mammalian cells. A plasmid (pCCL2 Trap) containing the CCL2 trap sequence was 
constructed in pCDNA3.1 vector under the control of CMV promoter. 
LPD NPs were constructed via a sequential self-assembly process (Figure 3.2A). First, 
blank cationic DOTAP: cholesterol liposomes were prepared with the thin-film method [239]. An 
anionic complex core was then formulated by mixing cationic protamine with plasmid DNA 
(pDNA). The anionic complex core was further coated by the blank cationic DOTAP: cholesterol 
liposome to formulate lipid-protamine-pDNA nanoparticle (LPD NP). To prolong the circulation 
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time and reduce non-specific uptake by Kupffer cells, polyethylene glycol (PEG) was coated on 
the surface of LPD NPs. Previous studies demonstrated that sigma receptor was significantly 
upregulated in 4T1 murine tumor [222]. A specific sigma receptor ligand, aminoethyl anisamide 
(AEAA), was employed to improve the local gene delivery and expression in 4T1 tumor. DSPE-
PEG and target ligand DSPE-PEG-AEAA were grafted on the surface of liposomes via post-
insertion method [239]. Final LPD NPs exhibited a uniform size of ~100 nm and a low 
polydispersity index (PDI<0.2) with neutral surface charge, as suggested by dynamic light 
scattering (DLS) analysis (Figure 3.2A, Supplemental figure 3.2).  
The final LPD NPs were labeled with a fluorescent lipophilic dye, DiI, to track the 
biodistribution of LPD NPs in 4T1 orthotopic tumor bearing mice. Twenty-four hours post 
intravenous injection of DiI-labeled LPD NPs, 4T1 tumor bearing mice were sacrificed, and major 
organs/tumors were subject to In Vivo Imaging Systems (IVIS) imaging. LPD NPs modified with 
target ligand AEAA predominantly accumulated within the breast tumor site, whereas non-
modified LPD NPs showed a non-specific biodistribution in liver and lung (Figure 3.2B). Based 
on the normalized fluorescence intensity analysis, a 1.5-fold increase of tumor specific uptake 
were achieved with AEAA modification, further verifying the successful tumor-targeted delivery 




Figure 3.2 Preparation and characterization of in situ CCL2 blockade depot. 
(A) Preparation and characterization of pCCL2 LPD NPs. DOTAP, 1,2-dioleoyl-3-trimethylammonium propane 
chloride salt. AEAA, aminoethyl anisamide. (B) The in vivo biodistribution of LPD NPs with or without AEAA 
modification in orthotopic 4T1 tumor bearing mice. Hydrophobic dye DiI was incorporated into the outer bilayer of 
LPD NPs as a fluorescent tracer. Twenty-four hours post intravenously injection of DiI-labeled LPD NPs, mice were 
sacrificed and tumors and major organs (liver, spleen, lung, heart, kidney) were harvested and examined under IVIS 




4.3. pCCL2 trap outperformed CCL2 mAb and remodeled the immunosuppressive TME in 
orthotopic 4T1 mouse model 
Inspired by the exciting target discovery and promising gene delivery platform, we wonder 
whether pCCL2 trap would generate a local and transient expression of CCL2 trap protein, remodel 
immunosuppressive TME and inhibit TNBC tumor progression as expected.  Animal experiments 
were conducted to evaluate the therapeutic efficacy of pCCL2 trap in 4T1 mouse orthotopic model 
as follows. LPD NPs encapsulating a plasmid encoding the green fluorescence protein (pGFP) 
were set as negative control. In addition, CCL2 mAb was included in the animal study aiming to 
investigate if pCCL2 trap could outperformed CCL2 mAb. Mice bearing 4T1 tumor were 
randomly divided into four groups and treated with different modalities shown in Figure 3.3A. 
Longitudinal tumor volume measurements were recorded every other day. In accordance with 
clinical studies, partial tumor inhibition effect was observed in CCL2 mAb treated group within 
the treatment schedule. Most importantly, the CCL2 level in the tumor was the lowest in the group 
treated with pCCL2 trap (Figure 3.3B). However, the rapid discontinuation of CCL2 mAb resulted 
in a rebound effect and accelerated tumor progression (Figure 3.3A). Further detailed flow 
cytometry analysis suggested that no significant decrease in M2 macrophage and MDSC was 
observed at the endpoint of the study. In contrast, the group treated with pCCL2 trap significantly 
inhibited tumor progression, with obviously down-regulated M2 macrophages and MDSC 
population lasting for two weeks following cessation of pCCL2 trap treatment (Figure 3.3C-D). 
Additionally, immunofluorescence staining revealed a remodeled TME in mice treated with 
pCCL2 trap. α-SMA, which was highly expressed in TAA and activated fibroblasts, was reduced 
by 3-fold after pCCL2 trap treatment compared with pGFP control group (p<0.001) (Figure 3.3E). 
The collagen content in different treatment groups was revealed with Masson Trichrome staining, 
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demonstrating a 4-fold decrease after pCCL2 trap treatment (p<0.0001) (Figure 3.3E). It is also 
noteworthy to mention plentiful normalized adipocytes (cells containing large oil droplets) were 
observed in pCCL2 trap treated group, suggesting the restoration of TAAs into normal adipocytes 
(Figure 3.3E). Furthermore, upon CCL2 trap treatment, T cell (CD3+ cells) infiltration within TME 
was increased by 5-fold compared with the pGFP treated group (p<0.001), which could be 
attributed to the remodeled immunosuppressive TME (Figure 3.3E).  
As an indispensable part of TME, cytokines and chemokines are important mediators and 
regulators for immune cell migration, infiltration and action. Highly elevated T cell recruiting 
cytokines including C-X-C Motif Chemokine Ligand 9 (CXCL9) and C-X-C Motif Chemokine 
Ligand 10 (CXCL10) are crucial for T cell infiltration. Furthermore, the activation of tumor 
infiltrating T cell also depends on proinflammatory Th1 cytokines, interleukin-12 (IL-12) and 
interferon gamma (IFN-γ). In accordance with previous T cell profiling, CXCL9, CXCL10, IL-12 
and IFN-γ were highly upregulated in pCCL2 trap treated group (p<0.01-0.001) (Figure 3.3F). 
Conversely, common matrix metallopeptidase (MMP) that involved in extracellular matrix (ECM) 
remodeling, such as MMP2, MMP9 and MMP 13, were significantly reduced compared with PBS 






Figure 3.3 pCCL2 trap outperformed CCL2 mAb and remodeled the immunosuppressive TME in 4T1 mouse 
model. 
(A) Tumor inhibition effect of PBS, pGFP, pCCL2 trap and CCL2 mAb. 1×106 4T1 cells were orthotopically injected 
into mammary fat pad of six-weeks female BALB/c mice on day 0. Mice were randomly distributed into 4 groups on 
day 7 (n=5). Tumor volume were recorded every other day by caliper measurement. Black arrow indicates the dosing 
schedule. **p<0.01. (B) The CCL2 mRNA expression in the tumor of mice received different treatments. Tumors 
were obtained at the end of the study (day 23, 10 days after the last treatment). *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. (C-D) The quantitative analysis of MDSC and M2 macrophage population within TME on day 23. 
Cells were measured by flow cytometry. MDSC, myeloid-derived suppressor cells. (E)  Upper panel, 
immunofluorescence staining of tumor samples from different treatment groups using anti-α-SMA antibody (green) 
and anti-CD3-antibody (red). Cell nuclei were stained as blue using DAPI. Lower panel, collagen contents quantified 
by Masson Trichrome staining. Five random fields were chosen for statistical analysis in each treatment groups. 
Images were analyzed by Image J software and quantified with GraphPad 6.0. *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. Scale bar represents 100 μm. (F) Relative mRNA expression of Th1 chemokines and cytokines in the 
tumor of mice received different treatments. Tumors were obtained at the end point of the study (day 23, 10 days after 
the last treatment). CXCL9: C-X-C Motif Chemokine Ligand 9; CXCL10: C-X-C Motif Chemokine Ligand 10; IL-
12: interleukin-12; IFN-γ: interferon gamma. *p<0.05, **p<0.01, ***p<0.001. (G) Relative mRNA expression of Th2 
chemokines and cytokines in the tumor of mice received different treatments. Tumors were obtained at the end point 
of the study (day 23, 10 days after the last treatment). MMP, metallopeptidase. PDGF-C, platelet-derived growth 
factor C. *p<0.05, **p<0.01, ***p<0.001. 
 
4.4. pCCL2 trap facilitated the checkpoint blockade therapy 
RNA sequencing data derived from The Cancer Genome Atlas (TCGA) database showed 
up-regulated expression of programmed cell death protein ligand 1 (PD-L1) in TNBC samples in 
comparison with non-TNBC samples [240]. PD-L1 is a checkpoint protein on tumor cells that 
negatively regulate the immune response by inactivating T cells [2]. Monoclonal antibodies that 
specifically block PD-L1 is referred as a checkpoint blockade therapy. The therapy effectively 
blocks the inhibition signal for T cell activation and initiates effective T cell based anti-tumor 
response [2]. However, TNBC patients do not respond well to checkpoint blockade therapy owing 
to the immunosuppressive TME [241]. Since the data above indicated that pCCL2 trap 
successfully remodeled the immunosuppressive TME, we wondered if pCCL2 trap treatment 
would enhance the checkpoint blockade therapy efficacy in our TNBC model. 
We have previously described a trap specifically blocking PD-L1 with an apparent Kd = 
219 pM ([242]). Plasmid pPD-L1 trap was formulated in LPD NPs and delivered to the orthotopic 
TNBC tumor in a manner similar to pCCL2 trap. Prior studies shown that pPD-L1 trap was 
efficiently generated local and transient PD-L1 trap expression in TME of 4T1 model with better 
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tolerance and lower immune-related adverse effects [149]. We next conducted a combination study 
to investigate the possible synergistic effect of pCCL2 trap and pPD-L1 trap in the orthotopic 4T1 
model. Despite the fact the pCCL2 trap or pPD-L1 trap by itself only showed a partial tumor 
inhibitory effect, tumor progression was significantly inhibited in the combined treatment group 
(Figure 3.4A-B). Further terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 







Figure 3.4. pCCL2 trap facilitate the checkpoint blockade-based therapy. 
(A) Tumor inhibition study of various treatments. Combo trap, the combination of pCCL2 trap and pPD-L1 trap. 
*p<0.05, **p<0.01, ***p<0.001. (B) Quantitative analysis of tumor weight of various treatment groups on day 26. 
*p<0.05, **p<0.01, ***p<0.00, ****p<0.0001. (C) TUNEL assay and corresponding quantitative analysis of tumor 
tissue from various treatment groups. TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling. 
Tumors were obtained on day 26. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
Breast tissue is enriched with adipocytes. Among all solid tumors, breast cancer is uniquely 
affected by these fat-containing cells as close neighbors. Normal adipocytes are characterized with 
large size and rich in the oil droplets. Adipocytes appeared in the tumor are smaller in size and less 
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enriched with oil droplets [227]. The role of TAA in tumor growth and tumor’s response to therapy 
is not entirely clear. Data in Figure 3.1 clearly indicated that tumor inoculated in the mammary fat 
pad grew faster and contained fewer infiltrated T-cells and more M2 type macrophages than the 
same tumor inoculated subcutaneously. The major difference in these two models is the presence 
of the adipocytes in TME. Our data suggested that subcutaneous tumor model is not a realistic 
model for human breast cancer.  
Our data and data from TCGA indicated the positive correlation of CCL2 with aggressive 
tumor growth and a highly immunosuppressive microenvironment in TNBC tumors.  The data in 
Figure 3.1 show the influence of tumor cells on the differentiation of normal adipocytes towards 
the TAA phenotype with a concomitant increase in CCL2 production. Monocytes expressing 
CCR2 and CCR4, receptors for CCL2, are recruited to the TME where they differentiate into M2 
macrophages and MDSCs. Both types of cell are strong contributors to the immunosuppressive 
microenvironment. It has been reported that TAA can gain a partial fibroblast activity and help to 
produce the fibrous extracellular matrix in TNBC. Interestingly, data in Figure 3.3 indicated that 
locally trapping CCL2 pushed the fibroblast-like TAAs back to the normal adipocyte phenotype. 
Since CCL2 is mainly produced by TAA, this chemokine must keep the TAA in the tumor 
associated phenotype, perhaps via an autocrine manner. Decrease in the CCL2 level would relieve 
the TAA from the tumor associated phenotype, characterized with a reduced production of 
collagen and increased level of oil droplet content (Figure 3.3). More importantly, reduction of the 
chemokine by the locally expressed trap has resulted in a significant remodeling of the TME, 
leading to tumor growth inhibition and enhanced activity of the checkpoint blockade (Figure 3.4). 
Our gene therapy strategy to deliver the trap protein to the TME outperformed the 
traditional mAb approach (Figure 3.3). It is not surprising that this was the case because the 
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AEAA-targeted NPs specifically delivered the trap gene to the tumor (Figure 3.2). In contrast, 
mAb distributes in the entire body. The trap protein (16 kDa), being much smaller than the IgG 
molecule (150 kDa), can readily diffuse in the TME and capture the target chemokine. Note that 
CCL2 is also a small protein (11-12 kDa). A large protein like IgG would experience serious 
diffusion hindrance in the desmoplastic TME in TNBC, much more so than small proteins.  
5. Conclusion 
We have designed a small trap protein with a relatively high affinity to bind CCL2 in a 
specific manner. This antibody-like protein was delivered to the TNBC tumor by using a gene 
therapy approach, resulting in a persistent decrease of CCL2 level in the tumor. Local delivery of 
the trap protein triggered a significant remodeling of the immune microenvironment and inhibited 
tumor growth. Since CCL2 is mainly produced by the TAAs in TNBC, our study demonstrated 
the usefulness in targeting TME to improve immunotherapy. In addition,  the NPs used in the study 
is rather simple to prepare, potentially in large scale, and non-toxic [239], the approach appears to 

























CHAPTER 4: TUMOR-TARGETED DELIVERY OF ARSENIC NANOPARTICLES 
EXERTS ANTI-TUMOR ACTIVITY THROUGH GENERATION OF DNA DAMAGE 
1. Summary 
Triple negative breast cancer (TNBC) is highly resistant to currently available therapeutic 
strategies. Arsenic is an FDA-approved chemotherapeutic drug with high antitumor cytotoxicity, 
demonstrating great potential for TNBC treatment. Cancer vaccine is a promising strategy for cold 
tumor, while clinical application is hindered by expensive personalized neoantigen identification 
and preparation. Arsenic is an FDA approved chemotherapy with high mutagenicity and toxicity. 
However, a tumor-specific delivery platform of arsenic to induce neoantigen repertoire and reduce 
toxicity in normal tissues is currently lacking.  Here we developed a tumor targeted delivery 
platform (LCA NPs) to specifically deliver arsenic into poorly immunogenic TNBC tumor to 
attempt generating a neoantigen repertoire for chemo-immunotherapy. LCA NPs achieved the 
tumor specific delivery and accumulation of arsenic, which is a key to induce mutation through 
DNA damage as shown by the comet assay. In addition, tumor-targeted delivery of arsenic 
successfully reprogrammed the immunosuppressive tumor microenvironment (TME), which was 
characterized with upregulation of immuno-stimulatory factors and downregulation of immuno-
inhibitory factors, significantly suppressing tumor growth in an orthotopic TNBC mouse model. 
The therapeutic activity of arsenic NPs depended on the host immune system, as depletion of either 
CD8 or CD4 cells completely abrogated the activity. Our work provided a feasible, effective and 
safe way for cancer vaccine development in TNBC, and opens up possibilities for the development 




Triple negative breast cancer (TNBC) is known as one of the most aggressive cancers that 
is characterized with high metastatic rate and poor survival prognosis [168, 170]. To date, the 
efficacy of treatment options for TNBC is low [173, 174]. In recent years, remarkable responses 
of anti-PD-L1 immunotherapy have been seen on cancers such as lung cancer and colorectal 
cancers, while similar success has not been achieved in TNBC patients [178-180]. TNBC is 
considered as an immunological “cold” tumor with low tumor mutation burden (TMB) and 
minimal T cell infiltration [182, 183]. Therefore, increasing TMB and T cell infiltration is the key 
to provok a strong immune response in TNBC patients [182]. 
High tumor immunogenicity can be achieved by generating tumor specific neoantigens. 
Chemotherapy and radiotherapy lead to the accumulation of DNA damage, which causes the 
formation of tumor-specific neoantigens [243]. The neoantigens further prime the tumor-specific 
T cells and mediate T cell infiltration into the poor immunogenic tumor microenvironment. In 
addition, the neoantigen mediated T cell therapy is fully tumor specific, which excludes the 
possibility of autoimmunity disease [29, 244, 245]. We expect that the mutagenesis inducers may 
induce tumor-specific neoantigens and evoke a robust anti-tumor immune response.  
Arsenic is a widely recognized cell mutation inducer [246, 247]. Arsenite (III) is an active 
form of therapy reagents (arsenic trioxide, Trisenox®), which has been approved by the FDA for 
the treatment of leukemia and hepatocellular carcinoma [248]. Arsenate (V) is the oxidized form 
of arsenite (III) with lower toxicity, but can be reduced to arsenite (III) by redox enzymes. 
However, the rapid clearance of arsenic from the bloodstream causes low accumulation within the 
tumor. In addition, non-specific tissue distribution of arsenic results in severe adverse effect [249].   
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Therefore, development of a tumor-targeted delivery vehicle is in urgent need to increase 
arsenic efficacy and bioavailability in solid tumors with minimal systemic toxicity.  
Recently, numerous nano-based strategies for drug delivery to tumors have been proposed 
[224] [250]. For example, surface modification with PEG has been widely utilized to reduce the 
opsonization of nanoparticles and minimize non-specific uptake by phagocyte within the 
reticuloendothelial system (RES) [250]. Our previous work has demonstrated that nanoparticles 
conjugated with aminoethyl anisamide (AEAA), which is a high affinity ligand (Kd = 9 nM) for 
sigma-1 receptor that is highly expressed in cancer cells, exhibit a tumor-targeted delivery to 4T1 
and CT26 cancer models [222] [251]. Furthermore, taking advantage of the acidic pH in tumor 
microenvironment (pH around 6.5) and in late endosome (pH around 5.5), a pH-dependent 
nanocarrier could achieve tumor-targeted arsenic release within the tumor cells while decrease the 
arsenic exposure in normal organs. 
Inspired by our previously developed lipidic calcium phosphate (LCP) nanoparticles 
(NPs), we developed a lipidic calcium arsenic (LCA) NPs with a pH-responsive drug release 
profile within the acidic tumor cell organelle [252]. Similar with phosphate, arsenic acid solution 
readily forms a biodegradable precipitate core within the liposomes. Mediated by AEAA ligand, 
LCA NP could be efficiently delivered to cancer cell via endocytosis and trapped into the 
endosomes. With the increased acidity within the endosome, an acid-mediated disruption enables 
release of the payload following rapid degradation of the LCA NP, releasing the arsenic payload 
to induce possible mutations and hopefully generate neoantigens. 
4T1 is a mouse triple negative breast cancer cell line [196]. Using 4T1 as a TNBC model, 
our work aims to identify the neoantigen repertoire generated by LCA NPs. Figure 4.1 illustrates 
our concept of employing LCA NPs to achieve tumor-targeted delivery of arsenic and further 
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generate neoantigen repertoire, resulting in robust anti-cancer immune response. We further 
conducted bioinformatic analysis to identify the mutation-derived neoantigens both in vitro and in 
vivo. The major histocompatibility complex (MHC) binding of the neoantigen peptide were 
evaluated by current available algorithms. These studies enhanced our mechanistic understanding 




Figure 4.1. Schematic illustration showing the mechanism by which LCA induce neoantigen repertoire in 
tumor bearing mice. 
(A) Lipidic calcium arsenic nanoparticles (LCA NPs) preparation. (B) Tumor bearing mice were intravenously 
injected with LCA NPs. (C) LCA NPs were preferentially delivered and accumulated within tumors owing to the 
enhanced permeability and retention effect (EPR) and target ligand modification (AEAA). A pH-dependent arsenic 
release profile was achieved within the acidic endosome. Arsenic further induce DNA damage and generate tumor 
specific neoantigen. (D) Neoantigens were recognized by dendritic cells, further activating tumor-specific T cell and 





3. Materials and Methods 
3.1. Cell lines and cell culture 
Murine triple-negative breast cancer cell line 4T1 were obtained from UNC Tissue Culture 
Facility and cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (V/V, 
Gibco) and 1% antibiotic-antimycotic (V/V, Gibco) at 37 C and 5% CO2 in a humified 
atmosphere following ATCC instructions. Cell lines have been tested for mycoplasma and none 
of those cell lines listed above tested positive. 
3.2. Preparations and characterization of LCA NPs 
The LCA NP was prepared with microemulsion technology to first form a calcium 
arsenite/arsenate nano-core and then coated with an amphiphilic anionic lipid, 
dioleoylphosphatidic acid (DOPA). Figure 1A shows a diagram for the preparation of the lipidic 
calcium arsenate (LCA) NP. Briefly, 250 mM CaCl2 and 250 mM NaHAsO4 or As2O3 aqueous 
solutions were prepared. The pH of the solution was adjusted pH 9 with NH4Cl. Fifty µL of CaCl2 
and 50 µL of NaHAsO4 (or As2O3) with DOPA were then dispersed in 7 mL cyclohexane/Triton-
X100/hexanol (7:2:1, V/V) to form two separate reverse water-in-oil micro-emulsions. After 
mixing the two emulsions for 15 min, 10 mL of ethanol is added to the mixture and the solution is 
stirred for 15 min. The mixed solution was centrifuged to collect the nano precipitates of 
Ca3(AsO4)2 (or Ca3(AsO3)2), which were then washed with ethanol. PEGylation and target 
modification are further added with outer layer lipids as described [252]. 1,2-dioleoyl-3-
trimethylammonium-propane (DOTAP), a cationic lipid, is added to the outer leaflet of the bilayer 
in order to enhance the endosomal lytic activity of NPs. Ten percent of the total PEGylated lipid 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-polyethylene glycol-2000 (DSPE-PEG), will 
contain aminoethyl anisamide (AEAA) as a targeting lipid (DSPE-PEG-AEAA). AEAA is a high 
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affinity (Kd = 9 nM) ligand for the sigma-1 receptor highly expressed in epithelial cancer cells 
including 4T1. Thus, NPs functionalized with AEAA target specifically to tumor cells. 
Size distribution and zeta potential of LCA NPs were determined by dynamic light 
scattering (DLS) with Zeta nanosizer Z. The morphology of LCA NP was characterized by 
transmission electron microscopy (TEM). The sample was dried on a carbon-coated copper grid 
before measurement.  
3.3. Mice  
Six-weeks old female BALB/c mice were purchased from Jackson Laboratories. All mice 
were maintained in pathogen-free conditions during the experiments. All animal handling 
procedures were approved by the University of North Carolina at Chapel Hill’s Institutional 
Animal Care and Use Committee.  
3.4. Breast orthotopic model 
1×106 4T1 cells were injected into the BALB/c mouse mammary fat pad. The size of the 
orthotopic tumors were measured manually and recorded as V (mm3) = 0.5×L×W2, in which L 
represents the length and W represents the width in millimeters.  
3.5. Comet Assay 
The single cell gel electrophoresis (comet) assay is a simple method for detection of DNA 
damage at the cellular level [253]. To evaluate the potential of arsenic to induce mutations I n 
vitro, we incubated the 4T1 cells with arsenite or arsenate solution. The extent of DNA damage 
was quantified as the intensity of the comet tail relative to the head. To evaluate the potential off-
target mutation in major organs (liver, spleen, lung), the LCA NPs (2.5 mg/kg) were given 
intravenously to 4T1 bearing mice. Cells were isolated from the organs after protease digestion 
and comet assay were done with these cells. 
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3.6. Pharmacokinetic Study 
Mice were injected with a single dose of 2.5 mg/kg free Arsenic or LCA via tail vain 
injection. Blood samples were collected by eye and cardiac puncture at different times after tail 
vein injection. The collected blood samples were centrifuged at 5,000 g for 10 min and plasma 
were obtained for ICP-MS analysis. The concentration-time curve and corresponding 
pharmacokinetics parameters of free arsenic and LCA were generated by 3P97 pharmacokinetic 
calculation program. 
3.7. Biodistribution study 
0.1% DiD were formulated in the lipid-bilayer of LCA nanoparticles. DiD-labeled LCA 
nanoparticles were intravenously injected to tumor-bearing mice. The biodistribution of the DiD-
labeled LCA nanoparticles in major organs were visualized and quantitated with the IVIS optical 
system 24 h after injection. The excitation wavelength was 640 nm and the emission wavelength 
was 670 nm for DiD staining.  
3.8.CD4+ and CD8+ T cells depletion study 
CD4 antibody (BioXcell, clone GK1.5) and CD8 antibody (BioXcell, clone 116-13.1) 
mediated CD4+ and CD8+ T cell depletion study in 4T1 tumor bearing mice were conducted 
throughout LCA treatment. Mice were intraperitoneally injected with 100µg of CD4 and CD8 
antibodies at day 7, day 11 and day 15, respectively. Mouse IgG2α isotype control (BioXcell, clone 
C1.18.4) were injected into the control groups mice. CD4+ and CD8+ T cell depletion were verified 
by FACS analysis. 
3.9. FACS analysis and immune cells profiling 
Immune cells within the tumor microenvironment were subjected to FACS analysis and 
profiling. Mice were sacrificed at the end point and fresh tumor tissues were collected. Fresh tumor 
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tissues were incubated with collagenase and DNase for 1 h at 37 C for 30 min at 37 C before 
minced and strained through cell strainer for single cell suspension. The cells were treated with 
ACK buffer to lyse the red blood cells and dispersed in FACS buffer. Single cell suspensions were 
then stained with a cocktail of fluorescently labeled antibodies for 0.5 h. Then the cells were fixed 
with 4% PFA and analyzed with FACS (BD LSR II). For intracellular staining, cells were first 
fixed and permeabilized for 30 min at 4 C then washed and stained with intracellular antibodies. 
All the antibodies used in the FACS analysis and profiling are provided in appendix II. 
3.10. Cell transfer experiments 
For adoptive T cell transfer experiment, T cells were obtained from the spleen of Balb/c 
mice. A total of 5×106T cells were transferred into a 4T1 tumor bearing recipient mice via tail vein 
injection. 
3.11. Immunofluorescence staining 
Fresh tumor and organ tissue taken from mice were fixed in 4% PFA, 15% and 30% sucrose 
solutions for 24 h at 4 C, respectively. Then tissues were embedded in optical cutting temperature 
embedding medium (Fisher Scientific), cut into 5 µm cryostat sections and attached to the 
positively charged slides. Slides were washed 3 times with PBS, permeabilized with 1% Triton X-
100 solution and blocked with 5% goat serum for 1 h. Slides were incubated with diluted primary 
solutions for 12 h at 4 C. Fluorescent secondary antibody were used if the primary antibody is not 
fluorescent. Stained sections were mounted in Prolong Gold Antifade Mountant with DAPI and 
imaged with LSM 710 confocal microscopy within 48 h. Five fields were randomly chosen for 
statistical analysis. Image J was used for quantitation and analysis. The antibodies used for 




3.12. Real-time PCR analysis 
Whole tumor RNA was extracted from freshly harvested tumor tissue via RNeasy 
microarray mini kit (Qiagen) and cDNA were obtained by reverse transcription via the iScriptTM 
cDNA synthesis kit (BIO-RAD) and amplified with Taqman gene expression master mix. Mouse 
specific primers were used and GAPDH was used as a reference gene. Reactions performed with 
the 7500 Real-Time PCR system and the data were analyzed with the 7500 software. The primers 
used for real-time PCR assay are listed in Table S2 
3.13. Toxicity and safety evaluation 
Mouse body weight and health conditions were carefully monitored every other day 
following the first treatment. At the endpoint of the study, mice were sacrificed, major organs, 
whole blood and serum were obtained at the endpoint. Blood chemistry analysis (ALT, AST, BUN, 
CREAT) was carried out to measure renal and hepatic functions. Whole blood analysis was carried 
out to measure myelosuppression. Major organs including heart, liver, spleen, lung and kidney 
were fixed and examined with H&E staining.  
3.14. TUNEL assay 
Apoptosis assay were conducted utilizing the TUNEL assay kit (DeadEndTM Fluorometric 
TUNEL System, Promega) following the manufacturer’s instructions. The tumor frozen slides 
were prepared and the fragmented DNA of apoptotic cells were stained with FITC and defined as 
TUNEL-positive nuclei. Stained sections were further mounted in Prolong Gold Antifade 
Mountant with DAPI and imaged with laser scanning confocal microscopy (Zeiss, LSM 710) 





3.15. Statistical Analysis 
All the quantitative results were expressed as mean ± SD. Two-tailed student’s t test was 
used for comparison within two groups and one-was analysis of variance (ANOVA) was used for 
comparison among multiple groups. GraphPad 6.0 was used for statistical analysis. P values less 
than 0.05 were considered to be statistically significant.  
4. Results and Discussion 
4.1. Lipidic calcium arsenic nanoparticles (LCA NPs) preparation and characterization 
The preparation and characterization of lipidic calcium arsenite/arsenate nanoparticles 
(LCA) were similar to that of LCP NPs [254]. The LCA NPs were prepared with microemulsion 
technology to first form a calcium arsenite/arsenate nano-core and then coated with an amphiphilic 
anionic lipid, dioleoylphosphatidic acid (DOPA). Figure 4.1A shows a diagram for the preparation 
of the lipidic calcium arsenate (LCA) NP. The core stabilized with DOPA contained nano 
precipitates of calcium arsenate [Ca3(AsO4)2] or calcium arsenite [Ca3(AsO3)2]. 1,2-dioleoyl-3-
trimethylammonium-propane (DOTAP), a cationic lipid, and cholesterol were added to the outer 
leaflet of the bilayer in order to enhance the endosomal lytic activity of NPs. PEGylation and target 
modification were further added with outer layer lipids as described [252]. Ten percent of the total 
PEGylated lipid 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-polyethylene glycol-2000 
(DSPE-PEG), contained aminoethyl anisamide (AEAA) as a targeting lipid (DSPE-PEG-AEAA). 
AEAA is a high affinity (Kd = 9 nM) ligand for the sigma-1 receptor highly expressed in epithelial 
cancer cells including 4T1. Thus, NPs functionalized with AEAA target specifically to tumor cells. 
Transmission electron microscopy and dynamic light scattering analyses suggested that LCA NPs 
exhibited well-dispersed spheres with average diameter of 70 nm and zeta potential of -5mV. The 
encapsulation efficacy of arsenic was about 85% as revealed by ICP-MS. 
95 
 
There are three main pH environments through the delivery route. This give rise to 
challenge of a pH-tuned delivery platform as the LCA NPs were exposed to different pH ranges 
in the delivery routes. Upon intravenous injection, the LCA NPs are exposed to blood and normal 
tissues which has a neutral pH around 7.4. LCA NPs were then preferentially delivered and 
accumulated within tumors owing to the enhanced permeability and retention effect (EPR) and 
target ligand modification.  It is well documented that tumor microenvironment has an acidic pH 
around 6.5 as a result of high rate of aerobic glycolysis in cancer cells (also known as Warburg 
effect).   Followed by binding to cell surface receptors and internalization, the LCA NPs were 
engulfed into the endosome where pH drops to 5 to 6. With increased acidity as the endosome 
ages, a pH-mediated disruption enables release of the payload following rapid degradation of the 
LCA NP. To evaluate the arsenic release profile from LCA NPs in different pH environments, 
release kinetics of arsenic from LCA NPS were conducted at pH 7.4, pH 6.5 and pH 5.5. Burst 
arsenic release were observed at pH 5.5 within the first few hours, suggesting the instability of Ca-
As precipitate core under acidic conditions. Sustained and slower release followed, demonstrating 
a possible steady controlled release kinetics within the endosome. It is also notable that even in 
pH 6.5 acidic conditions, the release rate was relatively low, indicating that minimal arsenic release 
could occur in the tumor stroma. Moreover, minimal arsenic release was detected at pH 7.4, 
indicating the stability of LCA NPs in normal physiological conditions which enabled prolonged 
drug retention within the circulation and in the tumor microenvironment. Stability of LCA in 
neutral or slightly acidic pH would allow reduced dosing frequency in therapy. In summary, the 
pH-dependent release profile of LCA NPs could effectively diminish arsenic drug release during 
blood circulation, increase precise intracellular release within the tumor cell.  
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Pharmacokinetics and biodistribution of LCA NPs were further characterized in vivo. The 
pharmacokinetics of LCA (III) and LCA (V) NPs were measured by ICP-MS and the data is shown 
in Figure 4.2D, fitting a one compartment model and indicating LCA NPs prolonged the half-life 
to 15-fold compared with free arsenic. To further investigate the tumor-targeted efficacy of LCA 
NPs, a hydrophobic dye DiD was incorporated into the outer bilayer of LCA NPs as a tracer. 
Twenty-four hours post intravenously injection of DiD-labeled LCA NPs, mice were sacrificed 
and tumors and major organs were harvested and examined using the IVIS Optical System (Figure 
4.2E). Compared with non-AEAA modified LCA NPS, AEAA modified LCA NPs achieved a 
significant higher tumor accumulation and retention. In addition, a significant lower LCA NP 
accumulation within major organs were observed, indicating the enhanced tumor-specific payload 
delivery and likely reduced toxicity were achieved with AEAA modified LCA NPs. Taken 
together, LCA NPs could effectively deliver and precisely release arsenic within tumor cells, 





Figure 4.2 LCA NPs preferentially accumulated in tumors and release arsenic in a pH-dependent way. 
A. Preparation of LCA NPs. In round bottom flask, CaCl2 and NaHAsO4 or As2O3 aqueous solutions were prepared 
and then dispersed in 7 mL cyclohexane/Triton-X100/hexanol (7:2:1, V/V) to form two separate reverse water-in-oil 
micro-emulsions. Two emulsions were mixed and nano precipitates of Ca3(AsO4)2 (or Ca3(AsO3)2) were formed and 
stabilized with DOPA. PEGylation and target modification are further added with outer layer lipids DOTAP and 
Cholesterol as described in the text. B. The transmission electron microscopy images of LCA (III) and LCA (V) NPs. 
C. Pharmacokinetic profile of free arsenic salt and LCA NPs. Free arsenic salt and LCA NPs were intravenously 
injected into 4T1 tumor bearing mice (N=4) via the tail vein. Blood concentrations at different time points are plotted. 
LCA NPs significantly prolonged the half-time of arsenic. D. The in vitro release kinetics of LCA (III) and LCA (V) 
NPs under different pH conditions measured by ICP-MS. E. In vivo biodistribution of LCA NPs with or without 
AEAA modification in 4T1 tumor bearing mice. Hydrophobic dye DiD was incorporated into the outer bilayer of 
LCA NPs as a tracer. Twenty-four hours post injection, mice were sacrificed and tumors and major organs were 
harvested and imaged by using an IVIS Optical System F. Quantitative analysis of DiD-labeled LCA NPs 




4.2.LCA NPs induce tumor-specific DNA damage 
Arsenic has been widely used as an effective chemotherapy in the clinical settings of 
various human cancers, such as leukemia and hepatocellular carcinoma [255-258]. Arsenic induces 
DNA damage by causing single/double strand breaks. In addition, relevant DNA repair enzymes 
may also be inhibited [255]. Comet scores are used to evaluate the DNA damage induced by 
arsenic [253, 259]. The extent of DNA damage was quantified as the intensity of the comet tail 
relative to the head and recorded as comet score. Our preliminary results indicate that arsenic salt 
can potently induce DNA damage (data not shown), which was also confirmed in previous 
literature [246, 247]. 
To evaluate the potential off-target mutation in major organs (liver, spleen, lung), either 
LCA (III) or LCA(V) NPs (2.5 mg/kg) were intravenously injected into mice bearing orthotopic 
4T1 tumors. Major organs, including the tumor, were harvested 24 h post injection. Comet assay 
was carried out with single cell suspensions prepared from these organs and tumors. Free As (III) 
or (V) induced a high level of comet scores in major organs such as liver, lung and spleen, but not 
in tumor, indicating high level of toxicities in the vital organs (Figure 4.3A and B). In contrast, 
LCA(III) or (V) did not induce any detectable comets in the normal organs, but only in the tumor 
tissue (Figure 4.3C and D). Taken together, these results indicated that LCA NPs could potentially 
induce cell mutation and generate neoantigen within tumor cells, while no obvious effect and 




Figure 4.3.  LCA NPs induce tumor-specific cell mutation and generate neoantigen repertoire. 
A. DNA damage and cell mutation in major organs and tumors in 4T1 tumor bearing mice treated with free arsenite 
or arsenate. 2.5 mg/kg arsenite or arsenate were intravenously injected into tumor bearing mice (N=4). Major organs 
and tumors were harvested and prepared into single cell suspensions for comet assay. B. Comet assay score of major 
organs and tumors from mice treated with free arsenite or arsenate. The extent of DNA damage was quantified as the 
intensity of the comet tail relative to the head and recorded as comet score. **p<0.01, comparing liver and tumor.  C. 
DNA damage and cell mutation in major organs and tumors in 4T1 tumor bearing mice treated with free arsenite or 
arsenate. 2.5 mg/kg LCA (III) or LCA (V) NPs were intravenously injected into tumor bearing mice (N=4). Major 
organs and tumors were harvested and prepared into single cell suspensions for comet assay. D. Comet assay score of 
major organs and tumors from mice treated with LCA (III) or LCA (V) NPs. ***p<0.001, comparing liver and tumor. 
 
4.3. Evaluation of anti-cancer effect of LCA NPs 
We further evaluated whether LCA NPs could show tumor growth inhibition in murine TNBC 
models. Lipidic calcium phosphate nanoparticles (LCP NPs) were employed as a negative control. 
LCP was prepared with a protocol similar to that of LCA (Figure 4.1), except phosphate was used 
to replace arsenate or arsenite. Calcium phosphate has no mutagenicity or other toxicities and 
serves as an excellent control for calcium arsenate or arsenite. Mice bearing 4T1 tumors were 
treated with PBS, LCP NPs, LCA (III) NPs and LCA (V) NPs separately. As shown in Figure 
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4.4A, A significant tumor inhibition effect was observed for mice treated with either LCA (III) or 
LCA (V) NPs, compared with LCP treated groups.  
Arsenic is a well-documented chemotherapy with known toxicity.   Questions arise as 
whether the observed tumor inhibition effect of LCA NPs was attributed to the potential 
neoantigen mediated immunotherapy or a purely chemotherapy. Tumor specific neoantigens are 
highly immunogenic peptides which can be processed and presented by dendritic cells and 
subsequently activate CD8+ and CD4+ T cells. To justify our hypothesis, we next examined the 
profile of tumor microenvironment in different treatment groups. Flow cytometry analysis 
revealed a significant increase (p<0.01) in T-cell infiltration, decrease in M2 type macrophages 
and MDSC populations, suggesting that the immunosuppressive TME was remodeled by LCA(III) 
and LCA (V) NPs treatment. Increased secretion of Th1 cytokines, especially those that act as T 
cell chemoattractant, such as C-X-C motif chemokine ligand 9 (CXCL9), C-X-C motif chemokine 
ligand (CXCL10), and IFN-γ were detected in LCA (III) and LCA (V) NP treated tumor samples. 
To further verify our hypothesis that the tumor inhibition effect was possibly caused by increased 
TMB and should be T cell dependent, we depleted the CD8+ T cells and CD4+ T cells separately 
with corresponding antibodies and therapy efficacy disappeared. These results indicated that LCA 
(III) and LCA (V) NPs could effectively induce a strong immune dependent therapy which was 
likely due to the generation of tumor specific neoantigen repertoire, resulting in remodeling the 
immunosuppressive tumor microenvironment. 
In clinic, tumors treated with chemotherapy or radiotherapy were analyzed to identify the 
treatment-induced neoantigens [29]. Checkpoint blockade immunotherapy is further applied to 
increase the T cell mediated cytotoxicity towards tumor specific antigens [260]. Recently, Wu et 
al designed and conducted the first-in-human personalized neoantigen therapy [204]. Patients’ 
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tumor samples were obtained and whole-exome sequencing analyses were performed to identify 
potential mutations. Potential neoantigens were predicted, screened, synthesized and used to 
immunize melanoma patients. Despite the fact that 4 out of 6 patients showed no disease 
recurrence, side effects such as mild flu-like symptoms, rash and fatigue were observed [204]. 
Additionally, the neoantigen prediction and vaccine manufacturing is time-consuming and 
expensive, which further hinder the broad clinical application. Another therapeutic strategy is 
chimeric antigen receptor (CAR) T–cell therapy [245]. CAR-T therapy employs genetically 
modified autologous T cells which specifically express CAR for the tumor antigen, followed by 
ex vivo cell expansion and infusion back to the patient. CAR-T therapy increases the number of 
tumor specific cytotoxic T cell to recognize and kill tumor cells. Improved recovery rates in 
leukemia patients were observed [8]. However, the clinical translation of CAR-T therapy was 
excluded from solid tumors as a result of several therapeutic barriers, such as CAR-T cell 
expansion, trafficking and infiltration within the immunosuppressive tumor microenvironment, 
among other factors [8]. In contrast, our strategy provides a simple and feasible approach to locally 
generate tumor specific antigens without the burden of personalized neoantigen analysis, 
prediction, antigen synthesis and vaccination. 
There are hot spot mutations that are specific for different mutagens [261, 262]. Arsenic 
could induce DNA damage through ROS generation  [263, 264]. ROS generation would further 
generate DNA adducts and DNA strand breaks  [265, 266]. Therefore, for a relatively weak 
mutagen such as arsenic, mutation pattern in the genome appears to be largely random. If so, the 
mutations generated in each individual will be different from each other. The mutation repertoire 
will then be selected by each individual’s major histocompatibility antigen (both class I and II), 
resulting in different neoantigens. Thus, although every patient will receive the same arsenic NPs 
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with same dose and dosing schedule, i.e., not personalized, the neoantigen outcome can be very 
different and personalized.  It would be an inexpensive way to do personalized medicine, a dream 










Figure 4.4 LCA NPs inhibited tumor growth in a T cell-dependent manner. 
 A. Tumor inhibition study of LCA (III) and LCA (V) NPs in 4T1 tumor bearing mice. LCP NP treated group was set 
as a negative control. Six-week female Balb/c mice were orthotopically injected with 1×106 cells on mammary fat 
pad. Mice were randomly distributed into 4 groups on day 7 (N=5). ***p<0.001. Mice were intravenously injected 
with PBS or LCP or LCA NPs on day 8, 10, 12 and 14. B. Quantitative analysis of tumor infiltrating T cells within 
tumor microenvironment in different treatment groups by flow cytometry. C-E. IFN-γ, CXCL9 and CXCL10 mRNA 
level in tumor microenvironment in different treatment groups by real-time PCR analysis. IFN-γ: interferon gamma; 
CXCL9: C-X-C motif chemokine ligand 9; CXCL10: C-X-C motif chemokine ligand 10. *p<0.05, **p<0.01, 
***p<0.001. F. Quantitative analysis of M2 macrophages within tumor microenvironment in different treatment 
groups by flow cytometry. *p<0.05, **p<0.01, ***p<0.001. G. Quantitative analysis of MDSC within tumor 
microenvironment in different treatment groups by flow cytometry. MDSC: myeloid-derived suppressor cells. 
*p<0.05, **p<0.01, ***p<0.001. H-I. IL-10 and TGF-β mRNA level in tumor microenvironment in different 
treatment groups by real-time PCR analysis. IL-10: interleukin 10; TGF-β: transforming growth factor beta. *p<0.05, 
**p<0.01, ***p<0.001. J. Tumor inhibition study in mice which were depleted CD4+ or CD8+ T cells with 
corresponding antibodies. Compromised tumor growth inhibition was observed in both CD4 and CD8 depleted mice. 
(N=4). ***p<0.001.  K. Tumor weight at the end point of CD4+ or CD8+ T cells depleted mice treated with LCP or 




Low TMB thwart the efficacy of immunotherapy in “cold” tumors. Increasing tumor TMB 
with mild mutagenesis agent arsenic, represents a clinically translatable strategy to overcome low 
immunogenicity in solid tumors. A tumor-targeted, pH-responsive delivery platform is the key for 
successful arsenic induced immunotherapy. LCA NPs precisely delivered arsenic into tumor cells 
to induce potential neoantigen-mediated immunotherapy, leveraging TMB and reprogramming 
immunosuppressive TME, and shown significant tumor inhibition effect in TNBC model. LCA 
NPs has opened up new possibilities for TNBC immunotherapy, which is a promising, feasible 
and affordable approach for the effective treatment of immunosuppressive “cold” tumor in clinics. 
Whether the LCA NP treatments have indeed generated mutations in the tumor and whether a 
neoantigen repertoire was produced will have to wait for future experiments in whole exome 


























CHAPTER 5: SUMMARY AND FUTURE PERSPECTIVES 
Breast cancer still remains to be the second killer in women in United States [241]. Triple-
negative breast cancer (TNBC) is further defined by the absence of estrogen (ER), progesterone 
(PR) and HER2 receptors [267]. TNBC patients account for 10-20% among all diagnosed breast 
cancer patients. TNBC is characterized as the most aggressive subtypes with high metastasis rate 
and poor survival [241]. In addition, limited therapeutic options are available for TNBC patients 
[267, 268]. 
Recent advances in checkpoint blockade therapy have redefined the cancer treatments 
[241]. However, barely success of PD-L1 or PD-1 inhibitor have been reported on TNBC patients. 
One major reason for the low response rate of checkpoint blockade therapy in TNBC patients is 
the presence of immunosuppressive TME, which characterized by minimal T cell infiltration, 
abundant immunosuppressive cells and low mutational load of the tumor cells [222, 241]. 
Therefore, modulation of TME is the key for the success of checkpoint blockade therapy in TNBC 
treatment [11]. Increased understanding of cancer biology provides several feasible strategies to 
remodel the TME and provoke immune response in TNBC treatment. 
As shown in Table 1.2, substantial studies have been undertaken for investigating the 
capacity and availability of NP-based delivery of immuno-regulatory agents to locally modulate 
the suppressive milieu within the TME. In addition, one of the major remaining challenges 
associated with clinical translation of nano-based immunotherapy (nanomedicine as well) is still 
the lack of efficient, safe delivery systems to facilitate the transport of therapeutic agents 
specifically to tumor sites following systemic administration [164]. In this thesis work, we aim to 
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design simple NP with clinical translation potential to deliver immuno-regulatory agents in a 
tumor-targeted manner to remodel the immunosuppressive TME in murine model of TNBC. 
The modulation of tumor microenvironment was achieved in two ways: increase the 
immunogenicity and decrease immunosuppressive components [269]. The development of cancer 
therapeutic vaccine was greatly advanced by nanotechnology. Nano platforms sufficiently deliver 
tumor-specific antigen to antigen presenting cells, leading to robust immune response. Traditional 
chemotherapy, radiotherapy and phototherapy were identified as immunogenic cell death (ICD)  
inducers, which employed dying tumor cells as a cancer vaccine [1]. On the other hand, attempts 
to decrease the TAM population within TME has also received success. Gene therapy-mediated 
reprogramming M2 macrophages to M1macrophages has shown great potential in preclinical 
models [237]. 
High tumor immunogenicity would be achieved by generation of ICD of tumor cells [1]. 
ICD is a special form of cell apoptosis which recruits and activates dendritic cells [270]. It further 
induces infiltration of activated T cells [1]. In Chapter 2, we formulated a liposome to deliver a 
potent ICD inducing agent, 17-AAG, in a tumor targeted manner to reverse the 
immunosuppressive TME and further facilitate the checkpoint blockade immunotherapy in murine 
TNBC model [222].  
Adipocytes are the primary cellular component within the TME in TNBC [225]. Breast 
cancer is uniquely affected by the adipocytes as close neighbors among all solid tumors. In Chapter 
3, we identified the role of tumor-associated adipocytes (TAA) in immunosuppressive TME in 
murine TNBC model. Our data demonstrated that TAA is the major source of C-C Motif 
Chemokine Ligand 2 (CCL2) which recruits monocytes to TME and further differentiated into M2 
macrophages and MDSCs. We first designed a small trap protein (CCL2 trap) with a relatively 
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high affinity to bind to CCL2 in a specific manner. Then we formulated the lipid-protamine-DNA 
nanoparticles (LPD NPs) to locally and transiently deliver a plasmid encoding CCL2 trap in a 
tumor-targeted manner to decrease the CCL2 level within TME. In addition, compared with CCL2 
mAb, our strategy showed an enhanced therapeutic efficacy and significant tumor growth 
inhibition.  
Previous studies revealed that response to immunotherapy is positively correlated with the 
mutational load of the tumor cells [244]. TNBC, as a cold tumor, is known for low mutational 
burden [244]. Increasing tumor mutational load with mild mutagenesis agent arsenic, represents a 
potentially translatable strategy to overcome low immunogenicity in solid tumors. Here in Chapter 
4 we formulated a tumor-targeted, pH-responsive delivery platform (LCA NPs) to precisely deliver 
arsenic into TME, leveraged TMB and reprogramming immunosuppressive TME, and shown 
significant tumor inhibition effect in TNBC model. Our formulation provided a feasible, effective 
and safe way for cancer vaccine development in TNBC, and opened up possibilities for the 
development of chemo-immunotherapy for immunosuppressive TNBC treatment.  
One obvious piece of future work is to verify if indeed the administration of LCA NPs has 
induced mutation in the tumor cells and has generated expected neoantigens. Whole exome 
sequencing will identify mutations in exons and RNAseq will identify and quantify potential 
neoantigens. More important is to examine if any unwanted mutations have been generated in 
normal tissues and organs, resulting in long term toxicities. These types of work are expensive and 
time consuming. I hope our lab will continue this line of work. 
Despite the fact that we gained much knowledge in those preclinical studies, we merely 
scratched the surface of the complex tumor microenvironment. First of all, the basic modulation 
of tumor microenvironment with immuno-regulatory modalities was done in animal models, which 
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differs from the human subjects, especially in the immunology system. Although some clinical 
samples have been obtained and analyzed by IHC or flow cytometry, the part cannot be taken as a 
whole. Different from most animal models, which tumors were derived from cell lines, human 
tumor samples consist of different cells with various mutations. Second, most of the nanoparticle-
based modalities are only approved to use in animals, the efficacy and safety are yet to be verified 
in humans. Third, complex formulation and process of proposed immunomodulatory nanoparticles 
are not easily translatable to the clinic. It should be borne in mind that complicated modifications 
of nanomaterials, which is hoped to achieve multifunctional delivery formulations with stabilizing 
groups, targeting ligands and bio-responsive linkers, may complicate the large-scale and 
reproducible production. Batch variations are expected, which may affect the reproducibility and 
become a regulatory approval hurdle. In addition, such extensive modifications may also cause 
unexpected toxicity. Therefore, further investigation must be performed to keep balance between 
the therapeutic benefit, the complexity of formulation preparation/scale-up and the risk of toxicity 
before nano-immunotherapies can be satisfactorily applied for cancer patients. Much more studies, 











APPENDIX I SUPPLEMENTAL DATA IN THE STUDY 
 
Supplemental figure 2.1 (A) The treatment schedule and tumor inhibition study of αPD-L1 in 4T1 model. (B) The 
CD3+ T cells infiltration in tumor microenvironment upon different treatment. (C) The western blot of HIF-1α assay 












Supplemental figure 2.2 (A) The immunofluorescence staining and corresponding quantitative analysis of the MCF-
7 cells treated by 17-AAG and PBS. HMGB1, high mobility group protein B1; CRT, calreticulin. Positive ratios were 
quantified based on 5 randomly chosen fields per treatment. *** p<0.001. (B) DC 2.4 cells were pulsed with condition 
medium for 24 h from 17-AAG treated MCF-7 cell. The scale bar represents 100 μm. (C) The expression of sigma 










Supplemental figure 2.3 The preparation process of 17-AAG lipo. The DOPC, cholesterol, 17-AAG and targeting 
ligand were dissolved in chloroform and mixed before added into a round bottom flask. After evaporation, the thin 






Supplemental figure 2.4 The characterization of 17-AAG liposomes. (A) The zeta potential of 17-AAG liposomes 
measured by DLS. (B) The in vitro drug release profile of 17-AAG liposomes with and without serum. (C) IC50 
values of free 17-AAG and 17-AAG liposomes in 4T1 and MCF-7 cell lines. *p<0.05. (D) In vitro cytotoxicity of free 




































































PBS 7.50.4 11.60.7 16.91.5 8.00.9 5.41.4 2.31.1 6.92.2 
Anti-PD-L1 7.60.7 10.10.6 15.90.7 8.11.1 6.12.3 2.20.9 5.11.7 
17-AAG 7.50.2 10.81.3 14.32.5 9.20.5 4.91.6 1.91.2 3.42.9 
Combo 7.20.5 11.40.9 13.02.3 8.72.1 5.62.1 2.40.4 7.31.3 
Normal 
Range 






Supplemental figure 3.1 (A) The CCL2 mRNA levels among different tissues/organs. (B) Representative clinical 
tumor tissue from TNBC patients, cited from The Human Protein Atlas. High expression of CCL2 was found in human 
TNBC samples. (C) High CCL2 expression correlates with shorter survival and poor prognosis in human TNBC. Data 














































APPENDIX II TABLE OF ANTIBODIES USED IN THE STUDY 
 
Antibody  Company  Catalog number  
α-SMA  Abcam  ab184675  
HIF1α Santa Cruz SC-10790 
CD3  Biolegend  100322  
CD8  Biolegend  100758  
CD4  Biolegend  100446 
CD62L  Biolegend  104420  
NK1.1  Biolegend  108718  
CD11b  Biolegend  101217  
Gr 1  Biolegend  108418  
CD1d  Biolegend  123508  
F4/80 Biolegend 123110 
CD206 Biolegend 141715 












































Primer  Company  Catalog number  
TGF-β  ThermoFisher Scientific  Mm01178820_m1  
CXCL9  ThermoFisher Scientific  Mm04279608_m1  
CCL2  ThermoFisher Scientific  Mm00441242_m1  
CXCL10  ThermoFisher Scientific  Mm04214185_m1  
PDGFC ThermoFisher Scientific  Mm00439560_m1  
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